thiazoles has been researched along with Insulin Sensitivity in 513 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (1.56) | 18.7374 |
| 1990's | 168 (32.75) | 18.2507 |
| 2000's | 284 (55.36) | 29.6817 |
| 2010's | 46 (8.97) | 24.3611 |
| 2020's | 7 (1.36) | 2.80 |
| Authors | Studies |
|---|---|
| Bouhsina, N; Dagher, E; Desfontis, JC; Lalanne, V; Mallem, MY; Moughaizel, M; Thorin, C | 1 |
| Chinetti, G; Le Garf, S; Le Menn, G; Mothe-Satney, I; Murdaca, J; Neels, JG; Rousseau, AS; Sibille, B | 1 |
| Ishii, Y; Kakefuda, R; Katsuda, Y; Maekawa, M; Ohta, T; Okuma, C; Sano, R; Sasase, T; Tadaki, H; Tomimoto, D; Yoshiuchi, H | 1 |
| Ader, M; Baskin, AS; Bergman, RN; Brychta, RJ; Cai, H; Cassimatis, TM; Cero, C; Chen, KY; Cypess, AM; Dieckmann, W; Fink, YA; Fletcher, LA; Herscovitch, P; Javitt, NB; Johnson, JW; Kapuria, D; Kelsey, N; Leitner, BP; Linderman, JD; McGehee, S; Millo, CM; O'Mara, AE; Piccinini, F; Rotman, Y; Sater, ZA; Walter, M; Walter, PJ | 1 |
| Jiang, W; Wang, J | 1 |
| Flier, JS | 1 |
| Mourad, AAE; Mourad, MAE | 1 |
| Chen, J; Confides, AL; Dupont-Versteegden, EE; El Khouli, RH; Finlin, BS; Johnson, ZR; Kern, PA; Memetimin, H; Morris, AJ; Sullivan, PG; Vekaria, HJ; Westgate, PM; Zhu, B | 1 |
| Ding, Y; Du, Y; Hu, S; Li, J; Li, X; Qi, J; Sun, K; Sun, Y; Wang, Y; Xu, R; Yao, G; Yao, J; Zhao, H; Zhu, Q; Zhu, Z | 1 |
| Adil, M; Ali, MR; Bawa, S; Paudel, YN; Sharma, M | 1 |
| Adil, M; Ali, MR; Basheer, AS; Bawa, S; Hassan, MQ; Paudel, YN; Shah, S; Sharma, M; Siddiqui, A | 1 |
| Ham, SA; Han, DW; Han, SG; Hur, J; Hwang, JS; Hwang, SI; Lee, CH; Lee, WJ; Paek, KS; Park, JA; Seo, HG; Shin, HC; Yoo, T | 1 |
| Ekblad, LL; Helin, S; Johansson, J; Jula, A; Laine, H; Puukka, P; Rinne, JO; Viitanen, M | 1 |
| de Oliveira, L; Graus-Nunes, F; Mandarim-de-Lacerda, CA; Rachid, TL; Silva-Veiga, FM; Souza-Mello, V | 1 |
| Jang, HJ; Jung, Y; Kim, SN; Kim, WJ; Kim, YK; Lee, W | 1 |
| Cheng, P; Liu, T; Shao, HG; Sun, YC | 1 |
| Copeland, KC; Dhaliwal, R; El Ghormli, L; Geffner, ME; Higgins, J; Levitsky, LL; Nadeau, KJ; Shepherd, JA; Weinstock, RS; White, NH | 1 |
| Okatan, EN; Olgar, Y; Tuncay, E; Turan, B | 1 |
| Bagci, R; Sahin, E; Sahinturk, V | 1 |
| Bojic, LA; Huff, MW | 1 |
| Aragno, M; Benetti, E; Chiazza, F; Collino, M; Fantozzi, R; Mastrocola, R; Minetto, MA; Rogazzo, M | 1 |
| Dolan, H; Egan, J; Ferrucci, L; Jeffrey Metter, E; Marano, C; O'Brien, RJ; Resnick, SM; Thambisetty, M; Troncoso, JC; Wong, DF; Yang, A; Zhou, Y; Zonderman, AB | 1 |
| Bandyopadhaya, A; Constantinou, C; Lee, S; Martyn, JA; Mindrinos, M; Psychogios, N; Rahme, LG; Tompkins, RG; Tzika, AA | 1 |
| Bojic, LA; Burke, AC; Chhoker, SS; Edwards, JY; Huff, MW; Pickering, JG; Sawyez, CG; Sutherland, BG; Telford, DE; Tirona, RG; Yin, H | 1 |
| Baldi, JC; Hofman, PL; Manning, PJ; Walker, RJ | 1 |
| Rajagopal, R; Semenkovich, CF | 1 |
| Baranowski, M; Chabowski, A; Górski, J; Mikłosz, A; Łukaszuk, B | 1 |
| Chew, GT; Sahebkar, A; Watts, GF | 1 |
| Asthana, S; Baker, LD; Bendlin, BB; Birdsill, AC; Christian, B; Craft, S; Hermann, BP; Johnson, SC; Jonaitis, EM; Koscik, RL; La Rue, A; Oh, J; Sager, MA; Statz, E; Willette, AA | 1 |
| Asiri, YI; Barr, AM; Boyda, HN; Honer, WG; Pang, CC; Procyshyn, RM; Wang, CK; Wu, C; Yuen, J | 1 |
| Advani, SL; Cummins, CL; Gilbert, RE; Kepecs, DM; Schroer, SA; Thai, K; Woo, M; Zhang, Y | 1 |
| Barroso, E; Chacón, MR; Ferrer, L; Maymó-Masip, E; Palomer, X; Rodríguez-Rodríguez, R; Salmerón, E; Salvadó, L; Vázquez-Carrera, M; Vendrell, J; Wabistch, M; Wahli, W | 1 |
| Aguila, MB; Magliano, DC; Mandarim-de-Lacerda, CA; Penna-de-Carvalho, A; Vazquez-Carrera, M | 1 |
| Cogolludo, Á; Duarte, J; Gálvez, J; Gómez-Guzmán, M; Hermenegildo, C; Jiménez, R; Pérez-Vizcaíno, F; Romero, M; Toral, M; Utrilla, MP; Zarzuelo, MJ | 1 |
| Gudas, LJ; Jessurun, J; Tang, XH; Trasino, SE | 1 |
| Cheng, JT; Ku, PM; Lee, KS; Niu, CS; Niu, HS | 1 |
| Freeman, R; Mogul, H; Nguyen, K | 1 |
| Atkins, AR; Downes, M; Evans, RM; Wall, CE; Yu, RT | 1 |
| Albrecht-Küpper, B; Dinh, W; Gheorghiade, M; Sabbah, HN; van der Laan, M; Voors, AA | 1 |
| Arslanian, S; Bacha, F; Caprio, S; El Ghormli, L; Goland, R; Haymond, MW; Levitsky, L; Nadeau, KJ; White, NH; Willi, SM | 1 |
| Adil, M; Akhtar, MS; Ali, MR; Bawa, S; Paudel, YN; Shah, S; Sharma, M; Wadhwa, R | 1 |
| Chen, W; Li, S; Liu, HY; Long, L; Wang, LL | 1 |
| De Marinis, L; Di Donna, V; Festa, R; Grande, G; Leone, E; Littarru, GP; Mancini, A; Meucci, E; Pontecorvi, A; Silvestrini, A; Tacchino, RM | 1 |
| Billin, AN | 1 |
| Becattini, B; Cellitti, JF; Chen, LH; De, SK; Emdadi, A; Karin, M; Kuntzen, C; Machleidt, T; Pellecchia, M; Riel-Mehan, M; Solinas, G; Stebbins, JL; Vazquez, J | 1 |
| DI, WJ; Ding, GX; Liu, J; Xie, Y; Yu, J; Zha, JM; Zhong, Y; Zhu, T | 1 |
| Barile, E; Chen, LH; Chen, V; Dahl, R; De, SK; Emdadi, A; Machleidt, T; Murphy, R; Pellecchia, M; Riel-Mehan, M; Stebbins, JL; Yuan, H | 1 |
| Borba, CP; Boxill, R; Cather, C; Copeland, PM; Evins, AE; Fan, X; Forstbauer, SI; Freudenreich, O; Goff, DC; Henderson, DC; Miley, K; Sharma, B | 1 |
| Khattab, MA | 1 |
| Artis, DR; Bollag, G; Erbe, DV; Gareski, T; Gartrell, K; Harding, K; Ibrahim, PN; Jalenak, M; Kubasiak, D; Lin, JJ; Mansour, TS; Panza, D; Perreault, M; Saiah, E; Tobin, JF; Vlasuk, GP; Wang, S; Will, S; Womack, P | 1 |
| Alvarez-Guardia, D; Barroso, E; Coll, T; Gómez-Foix, AM; Laguna, JC; Palomer, X; Vázquez-Carrera, M | 1 |
| Albaugh, VL; Breazeale, S; Elich, TD; Ilkayeva, O; Joyal, JL; Lang, CH; Lynch, CJ; Maresca, KP; Vary, TC; Wenner, BR | 1 |
| Bonen, A; Chabowski, A; Cresser, J; Dyck, DJ; Gulli, R; Ritchie, I; Stefanyk, LE | 1 |
| Aggarwal, S; Bhardwaj, TR; Kumar, M; Thareja, S | 1 |
| Cooney, GJ; Kraegen, EW; Li, HY; Sauerberg, P; Tid-Ang, J; Turner, N; Wulff, EM; Ye, JM; Zeng, XY | 1 |
| Fritsche, A; Häring, HU; Heni, M; Machicao, F; Ordelheide, AM; Staiger, H; Stefan, N; Thamer, C | 1 |
| Hanley, AJ; Harris, SB; Retnakaran, R; Ye, C; Zinman, B | 1 |
| Barroso, E; El Kochairi, I; Michalik, L; Palomer, X; Serrano-Marco, L; Vázquez-Carrera, M; Wahli, W | 1 |
| Cheng, P; Di, W; Ding, G; Kong, X; Liu, J; Lv, S; Qi, H; Wang, L; Wu, L; Yu, J; Zha, J; Zhang, A; Zhang, X; Zhong, Y | 1 |
| Cho, EJ; Choi, R; Choi, YS; Chung, CH; Kim, BH; Kim, HM; Lee, EY; Lee, MY; Naowaboot, J; Shin, JY; Shin, YG; Yang, YC | 1 |
| Hering, BD | 1 |
| Li, M; Lin, Y; Ma, Y; Zheng, Z | 1 |
| Cho, KY; Kim, DK; Lee, MK; Min, KM; Park, GS; Park, SW; Song, MS | 1 |
| Kamide, K; Kawano, Y; Minami, J; Tsunoda, S | 1 |
| Häring, HU; Stumvoll, M | 1 |
| Chakrabarti, R; Hiriyan, J; Kumar, MP; Kumar, SK; Mamidi, NV; Misra, P; Rajagopalan, R; Rao, CS; Suresh, J; Vikramadithyan, RK | 1 |
| Azen, SP; Berkowitz, K; Buchanan, TA; Goico, J; Hodis, HN; Kjos, SL; Marroquin, A; Ochoa, C; Peters, RK; Tan, S; Xiang, AH | 1 |
| Goldstein, BJ | 3 |
| Petersen, KF; Shulman, GI | 1 |
| Reusch, JE | 2 |
| Aljada, A; Dandona, P | 1 |
| Lebovitz, HE | 2 |
| Weissman, P | 1 |
| Kono, S | 1 |
| Ganaway, E; Garvey, WT; Kennedy, A; Rogers, NL; Wallace, P; Willi, SM | 1 |
| Hevener, AL; Javorschi, S; Kruszynska, YT; Norman, RA; Olefsky, JM; Sinha, M; Yu, JG | 1 |
| Iwatani, M; Wasada, T | 1 |
| Homma, H; Honda, T; Ide, H; Kawakami, Y; Ohno, K; Sakaue, S; Tagami, S; Yoshimura, H | 1 |
| Barnett, AH | 1 |
| Blanco, J; Robles, NR | 1 |
| Plutzky, J; Raji, A | 1 |
| Maruyama, T | 1 |
| Mori, Y; Sekihara, H | 1 |
| Yamanouchi, T | 3 |
| Toyota, T | 2 |
| Sugiyama, Y | 1 |
| Hiratani, K; Iwata, M; Kobayashi, M | 1 |
| Oka, Y | 1 |
| Hosaka, D; Imai, Y; Kawazu, S; Ohmura, E | 1 |
| Kitaoka, H | 2 |
| Kadowaki, T | 3 |
| Kadowaki, T; Yamauchi, T | 1 |
| Brathwaite, CE; Brebbia, JS; Fuhrer, J; Gelato, MC; McNurlan, MA; Mynarcik, DC; Quick, JL; Steigbigel, RT; Wax, MR | 1 |
| Desvergne, B; Escher, P; Michalik, L; Niesor, E; Rieusset, J; Touri, F; Wahli, W | 1 |
| Afaq, A; Blonde, L; Pathak, R | 1 |
| Montague, CT; Tugwood, JD | 1 |
| Kotake, H | 1 |
| Fujita, T; Ikeda, H; Kawamatsu, Y; Meguro, K; Sohda, T | 1 |
| Cooney, GJ; Dzamko, N; Ellis, B; Frangioudakis, G; Furler, SM; Iglesias, MA; Kraegen, EW; Ye, JM | 1 |
| Gin, H; Rigalleau, V | 2 |
| Craft, S; Watson, GS | 1 |
| Andersen, B; Brand, CL; Fleckner, J; Fledelius, C; Gotfredsen, CF; Hansen, BF; Sauerberg, P; Sturis, J; Wassermann, K; Ye, JM | 1 |
| Weldy, DL | 1 |
| Bar-Tana, J; Ben-Yaacov, L; Kalderon, B; Mayorek, N | 1 |
| Belz, U; Herling, AW; Juretschke, HP; Kalisch, J; Kleinschmidt, E; Kramer, W; Kuhlmann, J; Neumann-Haefelin, C; Stein, M | 1 |
| Bekins, SA; Raji, A; Seely, EW; Simonson, DC; Williams, GH | 1 |
| Dey, CS; Kumar, N | 1 |
| Asnani, S; Fonseca, VA; Gouda, BP | 1 |
| Kazdová, L; Kren, V; Krenová, D; Seda, O | 1 |
| Cleasby, ME; Livingstone, DE; Nyirenda, MJ; Seckl, JR; Walker, BR | 1 |
| Hayashi, Y; Imaeda, K; Itoh, M; Kamiya, F; Kato, T; Miyachi, N; Okayama, N; Shimizu, M; Takeuchi, T; Takeuchi, Y | 1 |
| Nakagawa, M; Onishi, T; Saibara, T; Saika, K; Shizuta, Y; Sugiura, T; Takeda, K; Toda, K | 1 |
| Cooney, GJ; Ellis, B; Iglesias, MA; Jensen, PB; Kraegen, EW; Larsen, PJ; Sørensen, RV; Wassermann, K; Watson, DG; Wood, L; Ye, JM | 1 |
| Barak, Y; Evans, RM; Miles, PD; Olefsky, JM | 1 |
| Yamada, N; Yatoh, S | 1 |
| Baron, AD; Hook, G; Paradisi, G; Shepard, MK; Steinberg, HO | 1 |
| Astrup, A; Larsen, TM; Toubro, S | 1 |
| Shaarawy, M; Shobokshi, A | 1 |
| Smith, SA; Tadayyon, M | 1 |
| Dandona, P | 1 |
| Brewer, B; Gavrilova, O; Gonzalez, FJ; Haluzik, M; Lambert, G; Matsusue, K; Reitman, ML; Ward, JM; Yim, SH | 1 |
| Bryer-Ash, M; Ghazeeri, G; Haas, D; Ke, RW; Kutteh, WH | 1 |
| Plosker, SM | 1 |
| Nesić, V; Stefanović, V; Stojimirović, B | 1 |
| Berger, GD; Berger, J; Doebber, T; Han, W; MacNaul, K; Moller, DE; Mosley, R; Sahoo, SP; Santini, C; Tolman, RL; Wu, M | 1 |
| Viberti, GC | 1 |
| Acerini, CL; Agostini, M; Bell, JD; Boiani, R; Chatterjee, VK; Cinti, S; Dixon, AK; Dunne, F; Gurnell, M; Jebb, SA; Karpe, F; O'Rahilly, S; Savage, DB; Tan, GD; Thomas, EL; Umpleby, AM; Vidal-Puig, A; Williams, RL | 1 |
| Fischer, S; Hanefeld, M | 1 |
| Festa, A; Gyimesi, A; Herz, M; Jermendy, G; Johns, D; Kerenyi, Z; Pavo, I; Schluchter, BJ; Shestakova, M; Shoustov, S; Tan, MH; Varkonyi, TT | 1 |
| Inoue, T; Kashiwabara, A; Kawasaki, T; Ogata, N; Sawashige, K; Sekino, N; Yamanouchi, T | 1 |
| Jones, NP; Jones, TA; Sautter, M; Van Gaal, LF | 1 |
| Tafuri, S; Wang, M | 1 |
| Basu, A; Kudva, YC; Zangeneh, F | 1 |
| Carter, L; Ciaraldi, TP; Henry, RR; Mudaliar, SR; Reehman, N; Wilmsen, HM | 1 |
| Boudoulas, H; Osei, K; Schuster, DP; Sparks, EA; Stakos, DA; Wooley, CF | 1 |
| Brass, LM; Bravata, DM; Horwitz, RI; Inzucchi, SE; Kernan, WN; McVeety, JC; Shulman, GI; Viscoli, CM | 1 |
| Azziz, R; Ehrmann, DA; Fereshetian, AG; Ghazzi, MN; Legro, RS; O'Keefe, M | 1 |
| Osawa, K; Ota, T | 1 |
| Chao, L; Chen, Y; Choi, H; Fillmore, JJ; Gavrilova, O; Haluzik, M; Higashimori, T; Kim, HJ; Kim, JK; Qu, X; Reitman, ML; Shulman, GI; Yu, C | 1 |
| Pugeat, M | 1 |
| Wyne, KL | 1 |
| Bell, DS | 1 |
| Chatterjee, VK; Gurnell, M; O'Rahilly, S; Savage, DB | 1 |
| Cutson, JJ; Dietz, KR; Gavrilova, O; Gonzalez, FJ; Haluzik, M; Johnson, L; Matsusue, K; Nicol, CJ; Reitman, ML; Vinson, C | 1 |
| Baillargeon, JP; Iuorno, MJ; Nestler, JE | 1 |
| Görtz, A; Lander, T; Reblin, T; Seidel, D; Stein, D | 1 |
| Stumvoll, M | 1 |
| Vigouroux, C | 1 |
| Odaka, H; Suzuki, M | 1 |
| Satoh, J | 1 |
| Bandyopadhyay, G; Beeson, M; Dizon, M; Farese, RV; Gomez-Daspet, J; Grebenev, D; Kanoh, Y; Miura, A; Powe, J; Sajan, MP; Standaert, ML | 1 |
| Havekes, LM; Mensink, RP; Muurling, M; Pijl, H; Romijn, JA; Voshol, PJ | 1 |
| Chen, L; Fisher, SJ; Gonzalez, FJ; Goodyear, LJ; Hirshman, MF; Jozsi, AC; Kahn, CR; Norris, AW; Ristow, M; Rosen, ED; Spiegelman, BM; Szanto, I | 1 |
| Bujo, H; Itou, T; Saito, Y; Shibasaki, M; Takahashi, K | 1 |
| Gaillard, T; Habash, D; Osei, K; Rhinesmith, S; Schuster, D | 1 |
| Bacon, BR; Brunt, EM; Neuschwander-Tetri, BA; Oliver, D; Wehmeier, KR | 1 |
| Barringhaus, KG; Chen, M; Czarnik, AC; Hesselbacher, S; Ley, K; Nadler, J; Phillips, JW; Sanders, JM; Sarembock, IJ; Yang, Z | 1 |
| Asaba, H; Auwerx, J; Doi, T; Hamakubo, T; Hamura, H; Iguchi, H; Ikeda, Y; Ioka, RX; Ito, S; Iwasaki, S; Kodama, T; Magoori, K; Naito, M; Sakai, J; Sumi, K; Tachibana, K; Tanaka, T; Uchiyama, Y; Watanabe, M; Watanabe, Y; Yamamoto, J; Yanagisawa, M | 1 |
| Assion, HJ; Schwenkreis, P | 1 |
| Sakai, J | 1 |
| Bailey, CJ; Day, C | 1 |
| Fredenrich, A; Gaudel, C; Grimaldi, PA; Holst, D; Jehl-Pietri, C; Lopez-Soriano, J; Luquet, S | 1 |
| Risto, E; Wu, XK | 1 |
| Butte, AJ; Hoberman, S; Joshi, M; Levy, J; Pappo, J; Pollard, J | 1 |
| Ishii, S; Kasayama, S; Kouhara, H; Kurebayashi, S; Shiraishi, M; Xu, X | 1 |
| Cobitz, A; Garber, A; Huang, C; Rood, J; Rosenstock, J | 1 |
| Biswas, N; Chou, H; Cobitz, A; Garber, A; Rood, J; Rosenstock, J | 1 |
| Correll, CU; Frederickson, AM; Kane, JM; Manu, P | 1 |
| Wooten, J | 1 |
| Björkstrand, E; Castro, VM; James, SR; Kaiser, C; Larsson, C; Nyhem, CS; Selén, G; Sundbom, M | 1 |
| Bachmann, W; Häring, HU; Kirsch, DM | 1 |
| Fujita, T; Iwatsuka, H; Kawamatsu, Y; Sohda, T; Sugiyama, Y; Suzuoki, Z; Taketomi, S | 1 |
| Chang, AY; Gilchrist, BJ; Wyse, BM | 1 |
| Gao, KM; Khoursheed, M; Lee, MK; Miles, PD; Moossa, AR; Olefsky, JM | 2 |
| Berti, L; Häring, H; Kellerer, M; Kiehn, R; Kroder, G; Mosthaf, L; Tippmer, S | 1 |
| Egawa, K; Hasegawa, M; Ide, R; Iwanishi, M; Kashiwagi, A; Kikkawa, R; Maegawa, H; Shigeta, Y; Ugi, S | 1 |
| Fukuda, H; Iritani, N | 1 |
| de Souza, CJ; Meglasson, MD; Robinson, DD; Ulrich, RG; Yu, JH | 1 |
| DeGrange, LM; Kaufman, LN; Peterson, MM | 1 |
| Buckingham, RE; Cawthorne, MA; Clark, MG; Colquhoun, EQ; Eldershaw, TP; Rattigan, S | 1 |
| Ikegami, H; Masuo, K; Mikami, H; Ogihara, T; Rakugi, H | 1 |
| Colca, JR; Hofmann, C; Lorenz, K; Palazuk, BJ; Williams, D | 1 |
| Daimon, M; Eguchi, H; Igarashi, M; Matsumoto, M; Sasaki, H; Sekikawa, A; Tominaga, M; Yamatani, K | 1 |
| Chisholm, DJ; Jenkins, AB; Kennedy, CJ; Kraegen, EW; Laybutt, DR; Oakes, ND | 1 |
| Beerdsen, P; Joyce, M; Ludvik, B; Nolan, JJ; Olefsky, J | 1 |
| Keen, H | 1 |
| Akazawa, S; Kawasaki, E; Matsumoto, K; Okuno, S; Takao, Y; Takino, H; Uotani, S; Yamaguchi, Y; Yamasaki, H; Yano, M | 1 |
| Colca, JR; Kurowski, TG; Ruderman, NB; Saha, AK | 1 |
| Abe, M; Ishii, J; Kashiwabara, H; Katayama, S; Kosegawa, I | 1 |
| Braithwaite, SS; Colca, JR; Hofmann, C; Hotamisligil, GS; Lorenz, K; Palazuk, BJ; Spiegelman, BM | 1 |
| Baum, ST; Bergman, RN; Elson, DF; Kemnitz, JW; Meglasson, MD; Roecker, EB | 1 |
| Colca, JR; Kostyo, JL; Towns, R | 1 |
| Iwanishi, M; Kobayashi, M | 1 |
| Bleasdale, JE; Swanson, ML | 1 |
| Haber, RS; Holand, A; O'Boyle, E; Weinstein, SP | 1 |
| Fujiwara, T; Horikoshi, H; Ikeda, K; Koike, H; Nishino, H; Okuno, A; Shiraki, T; Wada, M; Yoshioka, S | 1 |
| Kato, Y; Kawaguchi, M; Tanigawa, K | 1 |
| Umeda, F | 1 |
| Higa, S; Ishikawa, K; Mimura, G; Murakami, K; Takasu, N; Yagi, N | 1 |
| Boden, G; Chaiken, RL; Eckert-Norton, M; Gelfand, RA; Lebovitz, HE; Pasmantier, R; Ryan, I | 1 |
| Colca, JR; Corkey, BE; Cunningham, BA; Holbert, RI; Kurowski, TG; Ruderman, NB; Saha, AK | 1 |
| Berger, J; Biswas, C; Doebber, TW; Hayes, N; Ventre, J; Wu, M | 1 |
| Kotchen, TA | 1 |
| Kuehnle, HF | 1 |
| Dunaif, A; Finegood, D; Quintana, B; Scott, D; Whitcomb, R | 1 |
| Bailey, P; Berger, J; Biswas, C; Cullinan, CA; Doebber, TW; Hayes, NS; Leibowitz, MD; Saperstein, R; Smith, RG | 1 |
| Henry, RR | 1 |
| Kawamori, R; Yoshii, H | 1 |
| Olefsky, JM; Saltiel, AR | 1 |
| Boulanger, M; de Nanteuil, G; Duhault, J; Espinal, J; Herve, Y; Ravel, D | 1 |
| Chen, S; Izumida, T; Katayama, S; Noguchi, Y; Tatebe, J | 1 |
| Colca, JR; Fisher, RM; Kletzein, RF; Parker, TT; Tanis, SP | 1 |
| Connell, J; Petrie, J; Small, M | 1 |
| Giacca, A; Kawamori, R; Lekas, M; Matsuhisa, M; Rodgers, CD; Shi, ZQ; Vranic, M; Wan, C | 1 |
| Cornicelli, JA; Davis, JA; O'Rourke, CM; Saltiel, AR | 1 |
| Arakawa, K; Saku, K; Zhang, B | 1 |
| Bischoff, ED; Boehm, MF; Cesario, RM; Crombie, DL; Davies, PJ; Hamann, LG; Heyman, RA; Jow, L; Mondon, CE; Mukherjee, R; Nadzan, AM; Paterniti, JR | 1 |
| Reddy, SS; Speerhas, RA; Vidt, DG | 1 |
| Nestler, JE | 1 |
| Dunaif, A; Flier, JS; Mantzoros, CS | 1 |
| Hirose, T; Kurebayashi, S | 1 |
| Cavaghan, MK; Ehrmann, DA; Imperial, J; Polonsky, KS; Rosenfield, RL; Schneider, DJ; Sobel, BE | 1 |
| Fujita, H; Hatta, T; Itoh, H; Kawa, T; Kiyama, M; Miki, S; Moriguchi, J; Morimoto, S; Nakagawa, M; Nakamura, K; Nakata, T; Sasaki, S; Takeda, K; Uchida, A | 1 |
| Ishikawa, S; Iwamoto, Y; Kuzuya, T; Nagasaka, S; Saito, T | 1 |
| Akazawa, S; Chikuba, N; Ishibashi, M; Izumino, K; Matsumoto, K; Nagataki, S; Sakamaki, H; Takino, H; Tokuyama, K; Yamaguchi, Y; Yamasaki, H | 1 |
| Morimoto, Y; Nishikawa, K; Ohashi, M | 1 |
| Hamada, Y; Ikegami, H; Ogihara, T | 1 |
| Katayama, S | 1 |
| Anichini, R; Ferrannini, E; Foot, E; Gastaldelli, A; Pecori, N; Seghieri, G; Sironi, AM; Vichi, S | 1 |
| Auwerx, J; Berthault, MF; Doaré, L; Dugail, I; Ferré, P; Foufelle, F; Guerre-Millo, M; Hallakou, S; Kergoat, M; Morin, J | 1 |
| Cwik, C; Mishra, SK; Postlethwaite, AE; Rajanna, B; Solomon, SS | 1 |
| Ikeda, H; Nomura, C; Odaka, H; Suzuki, M | 1 |
| Kotchen, TA; Reddy, S; Zhang, HY | 1 |
| Arakawa, K; Ohta, T; Saku, K; Zhang, B | 1 |
| Hsueh, WA; Law, RE | 2 |
| Foley, J; O'Doherty, R; Stein, D | 1 |
| Cohen, A; Higo, K; Miles, PD; Olefsky, JM; Rafaat, K; Romeo, OM | 1 |
| Imano, E; Kajimoto, Y; Kanda, T; Kawamori, R; Yamasaki, Y | 1 |
| Burant, CF; Davidson, NO; Graves, RA; Hirano, K; Lohmiller, J; Lukens, J; Ross, S; Sreenan, S; Tai, TA | 1 |
| Camirand, A; Marie, V; Rabelo, R; Silva, JE | 1 |
| Sakamoto, N; Uno, T | 1 |
| Inoue, I; Ishii, J | 1 |
| Ikeda, H; Odaka, H; Sohda, T; Sugiyama, Y | 1 |
| Baba, S; Kaneko, T | 1 |
| Ciaraldi, T; Henry, RR | 1 |
| Hirayama, R; Niigata, K; Noshiro, O; Shikama, H; Shimaya, A; Yoneta, T | 1 |
| Buchanan, TA; Burant, CF; Cline, G; Gumbiner, B; Hsueh, WA; Inzucchi, S; Kelley, D; Maggs, DG; Nolan, J; Olefsky, JM; Polonsky, KS; Shulman, GI; Silver, D; Valiquett, TR | 1 |
| Hattori, J; Ishimori, M; Nakashima, K; Okumura, S; Sugimoto, M; Takami, K; Takami, R; Takeda, N; Yasuda, K; Yoshino, K | 1 |
| Akanuma, Y; Fujiwara, T; Horikoshi, H; Iwamoto, K; Kadowaki, T; Mori, Y; Okuno, A; Tamemoto, H; Tobe, K; Ueki, K; Umesono, K; Yazaki, Y | 1 |
| Kahn, SE; Porte, D; Prigeon, RL | 1 |
| Higo, K; Lee, MK; Miles, PD; Olefsky, JM; Rafaat, K; Romeo, OM | 1 |
| Campbell, LK; Campbell, RK; Johnson, MD | 1 |
| Ikeda, H; Murase, K; Odaka, H; Suzuki, M; Tayuki, N | 1 |
| Funahashi, T; Kameda-Takemura, K; Kihara, S; Matsuzawa, Y; Nakamura, T; Ouchi, N; Shinohara, E; Yamashita, S | 1 |
| Funahashi, T; Kihara, S; Matsuzawa, Y; Ouchi, N; Shinohara, E; Tamura, R; Yamashita, S | 1 |
| Baba, S; Eguchi, H; Hozumi, T; Ikeda, M; Ishida, Y; Kaneko, T; Kawamori, R; Kubota, M; Omori, Y; Sasaki, H; Sato, A; Shichiri, M; Tominaga, M; Uehara, M; Wasada, T; Yamasaki, Y | 1 |
| Bornkessel, B | 1 |
| Spiegelman, BM | 1 |
| Franciosa, MD; Greenberg, AS; Lien, P; Souza, SC; Yamamoto, MT | 1 |
| Demacker, PN; Smits, P; Stalenhoef, AF; Tack, CJ | 2 |
| Carlberg, C; Chiesi, M; Missbach, M; Pignat, W; Spanka, C; Wiesenberg, I | 1 |
| Lutterman, JA; Ong, MK; Smits, P; Tack, CJ | 1 |
| Greer, IA; Hopkinson, ZE; Sattar, N | 1 |
| Eriksson, KF; Groop, L; Nilsson, P | 1 |
| Hattori, J; Ishimori, M; Nakashima, K; Okumura, S; Sasaki, A; Sugimoto, M; Takami, K; Takami, R; Takeda, N; Yasuda, K; Yoshino, K | 1 |
| Hirano, T; Kazumi, T; Yoshino, G | 1 |
| Riddle, MC | 1 |
| Kobayashi, I; Mori, M; Sato, N; Shimizu, H; Shimomura, Y; Tsuchiya, T | 1 |
| Barnett, AH; Kumar, S; Lettis, S; Prange, A; Schulze, J | 1 |
| Kern, PA; Ranganathan, S | 1 |
| Arisaka, T; Ikebuchi, M; Ikeda, M; Kanda, T; Kawamori, R; Kinoshita, J; Kubota, M; Matsuhisa, M; Mochizuki, K; Niwa, M; Tohdo, R; Wada, M; Yamasaki, Y | 1 |
| Komers, R; Vrána, A | 1 |
| Mokuda, O; Sakamoto, Y | 1 |
| Kotchen, TA; Sonnenberg, GE | 1 |
| Bailey, ST; Ishii, S; Krakow, SL; Lazar, MA; Minami, C; Reginato, MJ; Tanaka, H | 1 |
| Berger, J; Doebber, T; Li, Z; McCrary, C; Moller, DE; Ryder, JW; Ventre, J; Woods, J; Wu, M; Zhang, B; Zierath, JR | 1 |
| Camp, HS; Johnson, JH; Ribon, V; Saltiel, AR | 1 |
| Ishii, S; Tanaka, H; Upton, R; Widdowson, PS; Williams, G | 1 |
| Fujii, S; Fujita, K; Ishii, T; Kurimasa, H; Mori, T; Sato, T; Tanaka, S; Yamakita, T; Yoshioka, K | 1 |
| Fonseca, VA; Granberry, MC | 1 |
| Hasegawa, I; Kurabayashi, T; Murakawa, H; Suzuki, M; Tanaka, K; Yamamoto, Y | 1 |
| Horikoshi, H; Ito, T; Shiomi, M; Tsujita, Y; Tsukada, T | 1 |
| McCarty, MF | 1 |
| Cooksey, RC; Garvey, WT; Hebert, LF; McClain, DA; Wofford, P; Zhu, JH | 1 |
| Furuya, H; Iwata, I; Kashiwagi, K; Kato, M; Nagafuchi, S; Niho, Y; Sekiguchi, N; Yamagata, A | 1 |
| Caro, JF; Kolaczynski, JW | 1 |
| Awata, T; Chen, S; Katayama, S; Kosegawa, I; Negishi, K | 1 |
| Elkind-Hirsch, KE; McWilliams, RB | 1 |
| Burant, CF; Cockburn, B; Fuller, T; Keck, S; Sreenan, S | 1 |
| Blonde, L; Guthrie, RD; Sandberg, MI | 1 |
| Kwon, G; Marshall, CA; McDaniel, ML; Xu, G | 1 |
| Buckingham, RE; Chattington, PD; Walker, AB; Williams, G | 1 |
| Arai, Y; Kaku, B; Mizuno, S; Moriuchi, I; Murakami, T; Nio, Y; Ohnaka, M; Ohsato, K; Takahashi, Y | 1 |
| Doi, K; Fukunaga, Y; Hosoda, K; Inoue, G; Itoh, H; Nakao, K; Nishimura, H; Tanaka, T; Yamori, Y; Yoshimasa, Y | 1 |
| Matsui, K; Shibata, T; Wakitani, K; Yonemori, F | 1 |
| Aoki, K; Kaneshiro, M; Kawasaki, S; Mukasa, K; Okamura, A; Saito, T; Satoh, S; Sekihara, H | 1 |
| Hoekstra, JB; Kuck, EM; Wagenaar, LJ | 1 |
| Andres, E; Blicklé, JF; Brogard, JM; Neyrolles, N | 1 |
| Lefèbvre, PJ; Scheen, AJ | 1 |
| Makino, H; Nishimiya, T; Ochi, M; Onuma, H; Osawa, H; Tang, Y | 1 |
| Daida, H; Mokuno, H; Ohmura, H; Sawano, M; Shimada, K; Sunayama, S; Watanabe, Y; Yamaguchi, H | 1 |
| Kurogi, Y | 1 |
| Ginsberg, H; Plutzky, J; Sobel, BE | 1 |
| Aizawa, S; Eto, K; Ezaki, O; Fujita, T; Hasegawa, G; Ishii, C; Kadowaki, T; Kitamura, T; Komeda, K; Kubota, N; Miki, H; Murakami, K; Naito, M; Nakano, R; Okuno, A; Satoh, S; Sekihara, H; Shiota, K; Sugiyama, T; Tamemoto, H; Tanaka, S; Terauchi, Y; Toyoshima, Y; Tsubamoto, Y; Yamauchi, T | 1 |
| Collier, G; Zimmet, P | 1 |
| Oberpichler-Schwenk, H | 1 |
| Hunabiki, A; Kasuga, M; Morita, S | 1 |
| Hattori, J; Kawachi, S; Nakashima, K; Okumura, S; Sasaki, A; Sugimoto, M; Takami, K; Takami, R; Takeda, N; Yasuda, K; Yoshino, K | 1 |
| Ide, T; Mochizuki, T; Murakami, K; Ohashi, M; Tsunoda, M | 1 |
| Smits, P; Tack, CJ | 1 |
| Clausson, P; Heinemann, L; Heise, T; Hirschberger, S; Rave, K | 1 |
| Cossy, J; Desmurs, JR; Kahn, PH; Menciu, C; Rakotoarisoa, H | 1 |
| Heerschap, A; Smits, P; Tack, CJ; Van Den Bergh, AJ; Van Den Boogert, HJ; Vervoort, G | 1 |
| Kasuga, M; Koike, T; Masugi, J; Mori, H; Tamori, Y | 1 |
| Yanase, T | 1 |
| Hamaguchi, T; Hanafusa, T; Matsuzawa, Y; Nakajima, H | 1 |
| Kuzuya, T | 2 |
| Ikeda, H; Murase, K; Sugiyama, Y | 1 |
| Shimizu, N | 1 |
| Kameda, N; Oka, Y; Okuya, S | 1 |
| Shimamoto, K | 1 |
| Kanazawa, Y; Kawano, M | 1 |
| Kataoka, K; Oguma, Y | 1 |
| Mabuchi, H; Yagi, K | 1 |
| Iwamoto, Y; Iwatani, M; Kamatani, N; Wasada, T | 1 |
| Kuzuya, H; Nakano, T; Yamada, K | 1 |
| Haneda, M; Isshiki, K; Kikkawa, R; Koya, D | 1 |
| Aoki, Y; Kawa, S; Kiyosawa, K | 1 |
| Iwamoto, Y; Sanaka, M | 1 |
| Matsui, J; Nakamura, J; Nakamura, T; Ogawa, Y; Suda, T | 1 |
| Fujita, S; Fujiwara, T; Hagisawa, Y; Isobe, A; Takamura, M; Yachi, M; Yamada, E; Yanagisawa, H | 1 |
| Lu, L; Schwartz, GG; Xu, Y; Zhu, P | 1 |
| Lefèbvre, PJ; Letiexhe, MR; Paquot, N; Scheen, AJ | 1 |
| Bailey, CJ; Nattrass, M | 1 |
| Juul Holst, J | 1 |
| Auwerx, J; Schoonjans, K | 1 |
| Horikoshi, H; Yachi, M | 1 |
| Anil Kumar, KL; Marita, AR | 1 |
| Daimon, M; Kato, T; Kimura, M; Manaka, H; Sasaki, H; Tominaga, M | 1 |
| Brinkmann, L; Goebel, FD; Michl, GM; Mühlbayer, D; Walli, R | 1 |
| Diamanti-Kandarakis, E; Zapanti, E | 1 |
| Chapman, H; Gould, GW; Lister, CA; Maier, VH; Melvin, DR; Murphy, GJ | 1 |
| Kruszynska, YT; Olefsky, JM; Sobel, BE; Yu, JG | 1 |
| Bailey, CJ | 1 |
| Walker, M | 1 |
| Westerbacka, J; Yki-Järvinen, H | 1 |
| Einecke, D | 1 |
| Bailey, CJ; Krentz, AJ; Melander, A | 1 |
| Miyamori, I; Oida, K; Takahashi, S | 1 |
| Arioglu, E; Duncan-Morin, J; Gottlieb, N; Herion, D; Hoofnagle, J; Kleiner, DE; Lieberman, J; Premkumar, A; Reitman, ML; Reynolds, J; Rother, KI; Sebring, N; Sumner, AE; Taylor, SI | 1 |
| Ganda, OP | 1 |
| Daida, H; Sunayama, S; Watanabe, Y; Yamaguchi, H | 1 |
| Cawthorne, MA; Crombie, DL; Heyman, RA; Hislop, DC; Liu, YL; Sennitt, MV | 1 |
| Olefsky, JM | 1 |
| Brown, KK; Glass, CK; Li, AC; Palinski, W; Silvestre, MJ; Willson, TM | 1 |
| Taylor, AE | 1 |
| Ludvik, B | 1 |
| Naruse, M; Tago, K; Takagi, S; Takano, K; Tanabe, A; Yoshimoto, T | 1 |
| Brindley, DN; Davidge, ST; Delrat, P; Jochemsen, R; Kelly, SE; O'Brien, SF; Pégorier, JP; Ravel, D; Russell, JC | 1 |
| Filz, HP | 1 |
| Kawano, Y; Minami, J; Okuda, N; Omae, T; Takishita, S | 1 |
| Aizawa, Y; Hasebe, N; Kawabe, J; Kikuchi, K; Takehara, N | 1 |
| Murphy, E; Nolan, JJ | 1 |
| Fujiwara, T; Horikoshi, H | 1 |
| Fujiwara, K; Hayashi, K; Nakamura, A; Ozawa, Y; Saruta, T; Tokuyama, H | 1 |
| Ducobu, J; Sternon, J | 1 |
| Esterbauer, H; Fürnsinn, C; Neschen, S; Oberkofler, H; Patsch, W; Waldhäusl, W | 1 |
| Campbell, IW | 1 |
| Hotta, N; Iguchi, A; Miura, H; Nakamura, J; Tamagawa, T; Tamaya, N; Uemura, K; Yoshioka, S | 1 |
| Henry, RR; Mudaliar, S | 1 |
| Bachmann, O; Häring, HU; Kausch, C; Krützfeldt, J; Machicao, F; Matthaei, S; Rett, K; Rettig, A; Stumvoll, M; Witke, A | 1 |
| Fonseca, VA; Granda-Ayala, R; Lee, TR; Parulkar, AA; Pendergrass, ML | 1 |
| Bloomgarden, ZT | 1 |
| Daubresse, JC | 1 |
| Ahima, RS; Bailey, ST; Banerjee, RR; Bhat, S; Brown, EJ; Lazar, MA; Patel, HR; Steppan, CM; Wright, CM | 1 |
| Grunberger, G; Miller, E; Patwardhan, R; Phillips, LS; Rappaport, EB; Salzman, A | 1 |
| Tooke, J | 1 |
| Reasner, CA | 1 |
| Iuorno, MJ; Nestler, JE | 1 |
| Johnson, WT; Stephens, TW; Yakubu-Madus, FE | 1 |
| Adachi, Y; Araki-Sasaki, R; Furuta, M; Gabazza, EC; Hori, Y; Katsuki, A; Murata, K; Sumida, Y; Tsuchihashi, K; Yano, Y | 1 |
| Aoki, K; Ito, S; Kikuchi, T; Mukasa, K; Nakajima, A; Okamura, A; Satoh, S; Sekihara, H | 1 |
| Sanyal, AJ | 1 |
| Banerji, MA; Lebovitz, HE | 1 |
| Akanuma, Y; Hagura, R; Hara, K; Ito, C; Kadowaki, T; Komeda, K; Kubota, N; Miki, H; Tamemoto, H; Terauchi, Y; Tobe, K; Yamauchi, T | 1 |
| Anai, M; Ando, K; Asano, T; Chiba, Y; Fujishiro, M; Fujita, T; Fukushima, Y; Inukai, K; Kikuchi, M; Ogihara, T; Onishi, Y; Ono, H; Sakoda, H; Sekine, N; Shojima, N | 1 |
| Kamimoto, M; Kohzuki, M; Sato, T; Wu, XM; Xu, HL; Yoshida, K | 1 |
| Akiyama, T; Fukumitsu, KI; Jia, DM; Otsuki, M; Tabaru, A | 1 |
| Bodkin, NL; Hansen, BC; Kliewer, SA; Lambert, MH; Lewis, MC; Oliver, WR; Plunket, KD; Russell, CS; Shenk, JL; Snaith, MR; Sternbach, DD; Sznaidman, ML; Willson, TM; Winegar, DA; Xu, HE | 1 |
| Peters, AL | 1 |
| Ito, T; Morita, H; Nakamura, H; Ohishi, H; Oki, Y; Suzuki, S | 1 |
| Fazio, S; Fogo, AB; Linton, MF; Ma, LJ; Marcantoni, C | 1 |
| Fajardo, ME; Malacara, JM; Nava, LE | 1 |
| Haruta, T; Ishibashi, O; Iwata, M; Kawahara, J; Kobayashi, M; Sasaoka, T; Takano, A; Takata, Y; Ueno, E; Uno, T; Usui, I | 1 |
| Harano, Y | 1 |
| Itoh, H; Nakao, K | 1 |
| Auclair, M; Capeau, J; Caron, M; Forest, C; Glorian, M; Vigouroux, C | 1 |
| Chang, CT; Chen, CC; Chen, RH; Sheen, LY; Shih, HC; Wang, HJ; Wang, TY | 1 |
| Akutsu, H; Funada, J; Otani, T; Sekiya, M; Suzuki, J; Watanabe, K | 1 |
| Ikeda, H; Sugiyama, Y | 2 |
| Buckingham, RE; Pickavance, LC; Wilding, JP | 1 |
| Castro Cabezas, M; Erkelens, DW; Halkes, CJ | 1 |
| Abe, I; Eto, K; Fujishima, M; Nakamura, Y; Ohya, Y | 1 |
| Inoue, Y; Momose, T; Moritan, T; Nagai, R; Ohtomo, K; Tateno, M; Yokoyama, I; Yonekura, K | 1 |
| Reaven, GM | 1 |
| Girard, J | 3 |
| Cooney, GJ; Kraegen, EW; Thompson, AL; Ye, J | 1 |
| Han, YQ; Kitakoshi, K; Nakai, N; Oshida, Y; Sato, Y | 1 |
| Bodkin, NL; Haney, J; Hansen, BC; Horikoshi, H; Ortmeyer, HK; Yoshioka, S | 1 |
| Burkey, BF; Chen, W; de Souza, CJ; Dong, M; Eckhardt, M; Gagen, K; Laurent, D | 1 |
| Lawrence, JM; Reckless, JP | 1 |
| Daida, H; Hoshi, S; Iwama, Y; Mokuno, H; Sawano, M; Shimada, K; Sunayama, S; Watanabe, Y; Yamaguchi, H | 1 |
| Iwamoto, Y; Kanamuro, R; Maruyama, S; Teno, S; Yanagisawa, K | 1 |
| Glazer, NB; Miskin, B; Prince, MJ; Robertson, KE; Rosenblatt, S | 1 |
| Chvojková, S; Divisová, J; Kazdová, L | 1 |
| Palazzolo, MR; Solomon, SS; Usdan, LS | 1 |
| Hodate, K; Itoh, T; Kushibiki, S; Mori, Y; Shingu, H; Shinoda, M; Ueda, Y; Yokomizo, Y | 1 |
| Jazet, IM; Meinders, AE | 1 |
| Akanuma, Y; Ide, T; Kadowaki, T; Kamon, J; Kimura, S; Komeda, K; Kubota, N; Miki, H; Motojima, K; Murakami, K; Nagai, R; Terauchi, Y; Tobe, K; Tsuchida, A; Waki, H; Yamauchi, T | 1 |
| Calvo Romero, JM; Lima Rodríguez, EM | 1 |
| Al-Majali, K; Betteridge, DJ; Kaplan, F | 1 |
| Brunmair, B; Fürnsinn, C; Gras, F; Neschen, S; Roden, M; Wagner, L; Waldhäusl, W | 1 |
| Hevener, AL; Janez, A; Olefsky, J; Reichart, D | 1 |
| Akanuma, Y; Ezaki, O; Fukayama, M; Hori, W; Ide, T; Itai, A; Kadowaki, T; Kagechika, H; Kamon, J; Kato, S; Kimura, S; Komeda, K; Kubota, N; Miki, H; Motojima, K; Murakami, K; Nagai, R; Shudo, K; Terauchi, Y; Tobe, K; Tsuboyama-Kasaoka, N; Tsuchida, A; Waki, H; Yamauchi, N; Yamauchi, T | 1 |
| Smith, U | 2 |
| Birkeland, KI | 1 |
| Auwerx, J; Bac, P; Blanchard, SG; Champy, MF; Desreumaux, P; Dubuquoy, L; Gelman, L; Leesnitzer, LM; Moras, D; Picard, F; Plunket, KD; Potier, N; Renaud, JP; Rocchi, S; Vamecq, J; Zeyer, D | 1 |
| Häring, H; Stumvoll, M | 1 |
| Finegood, DT; Topp, BG | 1 |
| Matthews, DR | 1 |
| Zinman, B | 1 |
| Makino, H; Nishimiya, T; Ochi, M; Onuma, H; Osawa, H; Sugita, A; Tang, Y | 1 |
| Adler, A; Bush, E; Kramer, D; Rondinone, CM; Shapiro, R | 1 |
| Yoshimasa, Y | 1 |
| Hotta, N | 1 |
| Beck-Nielsen, H; Brock, B; Madsbad, S; Schmitz, OE | 1 |
| Aguilar-Salinas, CA; Cesarman, G; Chavira-López, IJ; Fanghänel-Salmón, G; Gallegos-Martínez, J; Gómez-Diaz, RA; Gómez-Pérez, FJ; Guillén, LE; López, A; Salinas-Orozco, S; Sánchez-Reyes, L; Tamez, R; Torres-Acosta, EM; Vázquez-Chávez, C | 1 |
| Castro Cabezas, M; Erkelens, DW; van Dijk, H | 1 |
| Camejo, G; Ljung, B; Oakes, N | 1 |
| Berg, AH; Berger, J; Charron, MJ; Chatterjee, K; Combs, TP; Doebber, T; Gertz, BJ; Gottesdiener, KM; Larson, PJ; Moller, DE; O'Rahilly, S; Savage, DB; Scherer, PE; Tanen, M; Wagner, JA; Wang, WJ; Weiss, S; Zhang, BB | 1 |
| Lotz, N | 1 |
| Kasuga, M | 1 |
| Montague, CT | 1 |
| Brindley, D; Degerman, E; Holm, C; Holst, LS; Landström, TR; Manganiello, V; Mei, J | 1 |
| Lund, S; Pedersen, O; Vestergaard, H | 1 |
| Jia, DM; Otsuki, M | 1 |
| Ardecky, RJ; Bean, JS; Bensch, WR; Bilakovics, JM; Broderick, CL; Brooks, DA; Brozinick, JT; Dana, SL; Etgen, GJ; Johnson, WT; Kauffman, RF; Liu, S; McCarthy, JR; Misener, EA; Montrose, CR; Ogilvie, KM; Oldham, BA; Paterniti, JR; Rito, CJ; Shuker, AJ; Tyhonas, JS | 1 |
| Buckingham, RE; Clarke, K; Cole, MA; Desrois, M; Draper, NJ; Sidell, RJ | 1 |
| Laboureau-Soares Barbosa, S; Rodien, P; Rohmer, V | 1 |
| Tan, MH | 1 |
| Legro, RS | 1 |
| Grossman, LD | 1 |
| Scheen, A | 1 |
| Desouza, C; Dicker-Brown, A; Fonseca, V; Keebler, M; McNamara, DB; Murthy, SN; Poirier, LA | 1 |
| Adeli, K; Buckingham, R; Carpentier, A; Leung, N; Lewis, GF; Szeto, L; Taghibiglou, C; Uffelman, KD; Van Iderstine, SC | 1 |
| Cusi, K; DeFronzo, RA; Hardies, J; Mahankali, A; Mahankali, S; Mandarino, LJ; Matsuda, M; Miyazaki, Y | 1 |
| Chikara, S; Fukuda, N; Hu, WY; Kanmatsuse, K; Kishioka, H; Nakayama, M; Teng, J | 1 |
| Hattori, J; Ishimori, M; Nakashima, K; Okumura, S; Sugimoto, M; Takeda, N; Yasuda, K; Yoshino, K | 1 |
| Verspohl, EJ; Weiland, F | 1 |
| Scheen, AJ | 1 |
| Einhorn, D; Glazer, NB; Hershon, K; Rosenstock, J; Yu, S | 1 |
| Kane, JP | 1 |
| Demcáková, E; Klimes, I; Koranyi, L; Kürthy, M; Mogyorosi, T; Nagy, K; Seböková, E; Ukropec, J | 1 |
| Bíró, K; Jednákovits, A; Kukorelli, T; Kürthy, M; Mogyorósi, T; Nagy, K; Tálosi, L | 1 |
| Sewter, C; Vidal-Puig, A | 1 |
| Egawa, K; Iwanishi, M; Kobayashi, M; Shigeta, Y | 1 |
| Colca, JR; Hofmann, CA | 1 |
| Fujita, T; Ikeda, H; Meguro, K; Mizuno, K; Momose, Y; Sohda, T | 1 |
| Colca, JR; Edwards, CW; Hillman, RM; Hofmann, CA | 1 |
| Bowen, L; Shulman, GI; Stein, PP; Stevenson, R | 1 |
| Fujita, T; Ikeda, H; Shimura, Y; Sugiyama, Y; Taketomi, S | 1 |
| Ikeda, H; Shimura, Y; Sugiyama, Y | 1 |
| Andrews, KM; Gibbs, EM; Hutson, NJ; Kreutter, DK; Stevenson, RW | 1 |
| Fujita, T; Ikeda, H; Meguro, K; Shimura, Y; Sohda, T; Sugiyama, Y; Taketomi, S | 1 |
| Belin, D; Bruzzone, R; Trimble, ER | 1 |
| Chisholm, DJ; James, DE; Jenkins, AB; Kraegen, EW; Storlien, LH | 1 |
| Fujiwara, T; Horikoshi, H; Ushiyama, I; Yoshioka, S; Yoshioka, T | 1 |
| Fujita, T; Taketomi, S; Yokono, K | 1 |
| Mercer, SW; Trayhurn, P | 1 |
175 review(s) available for thiazoles and Insulin Sensitivity
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor δ: a multifaceted metabolic player.
Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Clinical Trials as Topic; Dyslipidemias; Hepatocytes; Humans; Inflammation; Insulin Resistance; Liver; Macrophages; Mice; PPAR delta; Thiazoles | 2013 |
New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
Topics: Acetates; Animals; Atherosclerosis; Chalcones; Cholesterol, HDL; Dyslipidemias; Fatty Liver; Fenofibrate; Humans; Insulin Resistance; Lipoproteins, HDL; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Propionates; Quinolines; Sulfonamides; Thiazoles; Triazoles; Triglycerides | 2014 |
Nuclear receptors and AMPK: can exercise mimetics cure diabetes?
Topics: Adipose Tissue; AMP-Activated Protein Kinases; Animals; Diabetes Mellitus; Energy Metabolism; Exercise; Exercise Therapy; Fibroblast Growth Factors; Homeostasis; Humans; Insulin Resistance; Liver; Mitochondria; Muscle, Skeletal; Oxidation-Reduction; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Peroxisome Proliferator-Activated Receptors; Receptors, Cytoplasmic and Nuclear; Sirtuins; Thiazoles | 2016 |
Partial Adenosine A1 Agonist in Heart Failure.
Topics: Adenosine; Adenosine A1 Receptor Agonists; Aminopyridines; Angina Pectoris; Animals; Anti-Arrhythmia Agents; Coronary Artery Disease; Diabetes Mellitus; Dipeptides; Drug Partial Agonism; Furans; Heart; Heart Failure; Humans; Insulin Resistance; Ischemic Preconditioning, Myocardial; Lipolysis; Mitochondria, Heart; Myocardium; Oxygen Consumption; Pyridines; Renal Insufficiency; Tachycardia, Supraventricular; Thiazoles | 2017 |
PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home.
Topics: Animals; Atherosclerosis; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Glucose; Humans; Insulin Resistance; Lipoproteins; PPAR delta; PPAR-beta; Propionates; Thiazoles | 2008 |
Targeting host factors: a novel rationale for the management of hepatitis C virus.
Topics: Antibodies; Antiviral Agents; Cyclophilins; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Nitro Compounds; Peroxisome Proliferator-Activated Receptors; Receptors, Cytoplasmic and Nuclear; Receptors, Estrogen; Receptors, Virus; Thiazoles; Virus Internalization | 2009 |
Protein tyrosine phosphatase 1B inhibitors: a molecular level legitimate approach for the management of diabetes mellitus.
Topics: Acetophenones; Amino Acid Sequence; Animals; Benzoates; Benzofurans; Biphenyl Compounds; Blood Glucose; Catalytic Domain; Catechols; Chromones; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Fluorides; Humans; Insulin; Insulin Resistance; Insulin Secretion; Janus Kinase 2; Models, Molecular; Naphthoquinones; Peptidomimetics; Phosphates; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Pyridazines; Receptor, Insulin; Signal Transduction; STAT3 Transcription Factor; Thiazoles; Thiazolidinediones; Thiophenes; Vanadium Compounds | 2012 |
Glitazones: clinical effects and molecular mechanisms.
Topics: Adipose Tissue; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Obesity; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Insulin resistance as the core defect in type 2 diabetes mellitus.
Topics: Adipose Tissue; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Obesity; Risk Factors; Thiazoles | 2002 |
Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Fatty Acids; Glucose; Glycogen; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Magnetic Resonance Spectroscopy; Muscle, Skeletal; Signal Transduction; Thiazoles | 2002 |
Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome.
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Resistance; Metabolic Syndrome; Physical Fitness; Risk Factors; Thiazoles; Thrombosis; Vasodilation | 2002 |
A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis.
Topics: Anti-Inflammatory Agents; Arteriosclerosis; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inflammation; Insulin; Insulin Resistance; Thiazoles | 2002 |
Rationale for and role of thiazolidinediones in type 2 diabetes mellitus.
Topics: Administration, Oral; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Metabolic Syndrome; Thiazoles | 2002 |
Reappraisal of the pharmacologic approach to treatment of type 2 diabetes mellitus.
Topics: Administration, Oral; Antihypertensive Agents; Biguanides; Diabetes Mellitus, Type 2; Glucosamine; Hormone Replacement Therapy; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Sulfonylurea Compounds; Thiazoles | 2002 |
[Insulin resistance in myotonic dystrophy].
Topics: Chromans; Humans; Hyperinsulinism; Insulin Resistance; Insulin-Like Growth Factor I; Myotonic Dystrophy; Myotonin-Protein Kinase; Protein Kinases; Protein Serine-Threonine Kinases; Thiazoles; Thiazolidinediones; Trinucleotide Repeats; Troglitazone | 2002 |
[Uric acid metabolism and insulin resistance in type 2 diabetes].
Topics: Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Humans; Hyperuricemia; Insulin Resistance; Thiazoles; Thiazolidinediones; Troglitazone; Uric Acid | 2002 |
Insulin-sensitizing agents--thiazolidinediones (glitazones).
Topics: Administration, Oral; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Approval; Europe; Humans; Hyperglycemia; Insulin; Insulin Resistance; Islets of Langerhans; Thiazoles; Thiazolidinediones; United Kingdom | 2002 |
[Antidiabetic agents and renal insufficiency].
Topics: Administration, Oral; Animals; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerulonephritis; Humans; Hyperglycemia; Hypoglycemic Agents; Inactivation, Metabolic; Insulin; Insulin Resistance; Kidney; Kidney Failure, Chronic; Liver; Renin-Angiotensin System; Thiazoles | 2002 |
Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions.
Topics: Adipose Tissue; Animals; Chromans; Coronary Artery Disease; Diabetes Mellitus; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Insulin Resistance; Lipoproteins; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2002 |
[Pharmacotherapies for type 1 diabetes mellitus].
Topics: Adjuvants, Immunologic; Animals; Biguanides; Chaperonin 60; Diabetes Mellitus, Type 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Islets of Langerhans; Niacinamide; Peptide Fragments; Peptides; Regeneration; Sulfonylurea Compounds; Thiazoles | 2002 |
[Adverse effects of oral hypoglycemic agents].
Topics: Acarbose; Administration, Oral; Biguanides; Cyclohexanes; Drug Interactions; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Nateglinide; Phenylalanine; Pioglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 2002 |
[Insulin sensitizer drugs--review].
Topics: Adipose Tissue; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
[Glitazone--a new drug for type 2 diabetes].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Lipid Metabolism; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
[Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects].
Topics: Animals; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Lipid Metabolism; Obesity; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
[Pioglitazone].
Topics: Animals; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Edema; Humans; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2002 |
[Rosiglitazone (BRL-49653)].
Topics: Animals; Carbohydrate Metabolism; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Treatment Outcome | 2002 |
[Combination therapy of insulin sensitizer, thiazolidinedione drugs, and sulfonylurea].
Topics: Blood Glucose; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
[Efficacy of combination therapy of alpha-glucosidase inhibitor and insulin sensitizer in patients with type 2 diabetes].
Topics: Acarbose; Animals; Biguanides; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin Resistance; Pioglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
[Perspective for development of insulin sensitizers].
Topics: Drug Design; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
[Chemical structures and pharmacological characteristics of novel non-thiazolidinedione insulin sensitizer (JTT-501, FK614)].
Topics: Animals; Blood Glucose; Drug Design; Humans; Hypoglycemic Agents; Insulin Resistance; Isoxazoles; Lipid Metabolism; Oxadiazoles; Receptor, Insulin; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
[Mechanisms by which PPAR gamma modulators regulate insulin sensitivity].
Topics: Adipocytes; Animals; Apoptosis; Cell Differentiation; CREB-Binding Protein; Diabetes Mellitus, Type 2; Drug Design; Humans; Hypoglycemic Agents; Insulin Resistance; Nuclear Proteins; Polymorphism, Genetic; Receptors, Cytoplasmic and Nuclear; Thiazoles; Trans-Activators; Transcription Factors | 2002 |
Thiazolidinediones in the treatment of managed care patients with type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperlipidemias; Hypoglycemic Agents; Inflammation; Insulin Resistance; Islets of Langerhans; Managed Care Programs; Mice; Outcome Assessment, Health Care; Thiazoles; Thiazolidinediones; United States | 2002 |
Biology and toxicology of PPARgamma ligands.
Topics: Diabetes Mellitus, Type 2; DNA-Binding Proteins; Humans; Hyperlipidemias; Hypoglycemic Agents; Inflammation; Insulin Resistance; Ligands; Microbodies; Nuclear Proteins; Receptors, Cytoplasmic and Nuclear; Repressor Proteins; Thiazoles; Thiazolidinediones; Transcription Factors; Zinc Fingers | 2002 |
[Syndrome X].
Topics: Animals; Bezafibrate; Biguanides; Fatty Acids, Nonesterified; Humans; Hyperglycemia; Hyperinsulinism; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Leptin; Life Style; Metabolic Syndrome; Pioglitazone; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2002 |
[Discovery and development of a new insulin sensitizing agent, pioglitazone].
Topics: Animals; Clinical Trials as Topic; Clofibrate; Diabetes Mellitus; Diabetes Mellitus, Experimental; Drug Design; Humans; Hypoglycemic Agents; Insulin Resistance; Mice; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
Oral anti diabetic polychemotherapy in type 2 diabetes mellitus.
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Thiazoles; Thiazolidinediones | 2002 |
The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment.
Topics: Alzheimer Disease; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Effects of thiazolidinediones on cardiovascular risk factors.
Topics: Arteriosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fibrinolysis; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Risk Factors; Thiazoles; Vascular Resistance; Weight Gain | 2002 |
Insulin sensitizers and atherosclerosis.
Topics: Animals; Arteriosclerosis; Glucose Intolerance; Humans; Insulin; Insulin Resistance; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors | 2002 |
PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy?
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Obesity; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Insulin sensitisation in the treatment of Type 2 diabetes.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adrenergic beta-3 Receptor Agonists; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Hydroxysteroid Dehydrogenases; Hypoglycemic Agents; Insulin; Insulin Resistance; Islets of Langerhans; Metformin; Peptide Fragments; Protein Precursors; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Thiazoles; Transcription Factors | 2003 |
Insulin resistance and endothelial dysfunction in atherosclerosis: implications and interventions.
Topics: Arteriosclerosis; Cardiovascular Diseases; Endothelium, Vascular; Humans; Insulin Resistance; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors | 2002 |
Polycystic ovary syndrome and insulin resistance.
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Polycystic Ovary Syndrome; Prevalence; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; United States; Women's Health | 2003 |
Treatment of insulin resistance in uremia.
Topics: Anemia; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Diabetes Mellitus, Type 2; Erythropoietin; Humans; Hyperparathyroidism; Hypoglycemic Agents; Insulin Resistance; Phosphoric Diester Hydrolases; Pyrophosphatases; Recombinant Proteins; Renal Dialysis; Thiazoles; Thiazolidinediones; Uremia | 2003 |
Rosiglitazone: potential beneficial impact on cardiovascular disease.
Topics: Albuminuria; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperglycemia; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Obesity; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Male; Metformin; Middle Aged; Obesity; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis.
Topics: Animals; Arteriosclerosis; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Models, Biological; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Insulin sensitizers.
Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Thiazoles; Thiazolidinediones | 2003 |
[Treatment of PCOS without IVF: weight loss, insulin-sensitizing agents].
Topics: Acarbose; Chromans; Enzyme Inhibitors; Female; Glucose Intolerance; Glucosidases; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Metformin; Polycystic Ovary Syndrome; Thiazoles; Thiazolidinediones; Troglitazone; Weight Loss | 2003 |
The need for reappraisal of type 2 diabetes mellitus management.
Topics: Diabetes Mellitus, Type 2; Gluconeogenesis; Humans; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Primary Prevention; Risk Factors; Thiazoles; Thiazolidinediones | 2003 |
Beneficial effects resulting from thiazolidinediones for treatment of type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Thiazoles; Thiazolidinediones | 2003 |
The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation.
Topics: Adipose Tissue; Animals; Arteriosclerosis; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Mutation; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
The relationship of obesity to the metabolic syndrome.
Topics: Adiponectin; Adipose Tissue; Blood Proteins; Body Constitution; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Metabolic Syndrome; Obesity; Proteins; Thiazoles; Thiazolidinediones | 2003 |
Insulin sensitizers for polycystic ovary syndrome.
Topics: Chromans; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
Thiazolidinediones -- some recent developments.
Topics: Adipose Tissue; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors | 2003 |
[Lipodystrophies: what treatment?].
Topics: Antiviral Agents; Diabetes Complications; Diabetes Mellitus; Diet; Exercise; HIV-Associated Lipodystrophy Syndrome; Humans; Insulin Resistance; Metformin; Thiazoles; Thiazolidinediones | 2003 |
[Hypertension and insulin resistance in obese type 2 diabetic Wistar fatty rat].
Topics: Animals; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Models, Animal; Hyperinsulinism; Hypertension; Hypoglycemic Agents; Insulin Resistance; Obesity; Pioglitazone; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones | 2003 |
[Insulin-sensitizing agents: metformin and thiazolidinedione derivatives].
Topics: Adipocytes; Adiponectin; Cyclic AMP-Dependent Protein Kinases; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glycerol Kinase; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Metformin; Obesity; Proteins; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Atypical antipsychotics and diabetes mellitus.
Topics: Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus; Dibenzothiazepines; Glucose; Humans; Insulin Resistance; Islets of Langerhans; Obesity; Olanzapine; Pancreas; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles | 2004 |
[Activation of "fat burning sensor" peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome].
Topics: Animals; CCAAT-Enhancer-Binding Proteins; DNA-Binding Proteins; Fatty Acids; Glucose Tolerance Test; Humans; Insulin Resistance; Kruppel-Like Transcription Factors; Life Style; Metabolic Syndrome; Mice; Mice, Transgenic; Multigene Family; Muscle, Skeletal; Nuclear Proteins; Oxidation-Reduction; Receptors, Cytoplasmic and Nuclear; Sterol Regulatory Element Binding Protein 1; Thiazoles; Transcription Factors; Transcription, Genetic | 2004 |
Avandamet: combined metformin-rosiglitazone treatment for insulin resistance in type 2 diabetes.
Topics: Contraindications; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Thiazoles; Treatment Outcome | 2004 |
Roles of peroxisome proliferator-activated receptor delta (PPARdelta) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome.
Topics: Adipose Tissue; Animals; Fatty Acids; Insulin Resistance; Ligands; Macaca mulatta; Metabolic Syndrome; Muscle, Skeletal; Obesity; PPAR delta; Thiazoles | 2004 |
Metabolic effects of the atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Dyslipidemias; Glucose Metabolism Disorders; Humans; Insulin Resistance; Mental Disorders; Obesity; Olanzapine; Phenothiazines; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2007 |
Potential role of thiazolidinediones in older diabetic patients.
Topics: Aged; Aging; Animals; Benzopyrans; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin Resistance; Japan; Mice; Pioglitazone; Randomized Controlled Trials as Topic; Rats; Thiazoles; Thiazolidinediones; Troglitazone | 1995 |
Attenuation of hypertension by insulin-sensitizing agents.
Topics: Animals; Blood Pressure; Humans; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Thiazoles | 1996 |
New therapeutic agents for the treatment of NIDDM.
Topics: Animals; Carbonates; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Molecular Structure; Prevalence; Thiazoles | 1996 |
Effects of troglitazone on insulin sensitivity.
Topics: Animals; Blood Glucose; Blood Pressure; Chromans; Diabetes Mellitus, Type 2; Glucose Intolerance; Glucose Tolerance Test; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Obesity; Thiazoles; Thiazolidinediones; Troglitazone | 1996 |
[Drug therapy in subjects with impaired glucose tolerance].
Topics: Acarbose; Biguanides; Chromans; Diabetes Mellitus, Type 2; Glucose Intolerance; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Insulin Resistance; Metformin; Pioglitazone; Risk Factors; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Trisaccharides; Troglitazone | 1996 |
Thiazolidinediones in the treatment of insulin resistance and type II diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Gene Expression Regulation; Humans; Insulin Resistance; Lipids; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors | 1996 |
Troglitazone: a new antihyperglycemic agent.
Topics: Chromans; Diabetes Mellitus, Type 2; Gluconeogenesis; Humans; Hypoglycemic Agents; Insulin Resistance; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.
Topics: Adrenal Glands; Androgens; Anovulation; Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Ovary; Polycystic Ovary Syndrome; Steroid 17-alpha-Hydroxylase; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
[Adipocyte differentiation and nuclear receptor].
Topics: Adipocytes; Cell Differentiation; Chromans; Diabetes Mellitus; Humans; Hypoglycemic Agents; Insulin Resistance; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 1997 |
[Insulin, as a regulating factor of blood pressure].
Topics: Animals; Cell Division; Chromans; Humans; Hyperinsulinism; Hypertension; Hypoglycemic Agents; Insulin; Insulin Resistance; Kidney; Muscle, Smooth, Vascular; Sodium; Sympathetic Nervous System; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
[Treatment of hypertension associated with diabetes mellitus].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cerebrovascular Disorders; Chromans; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Risk Factors; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Pharmacological treatment and mechanisms of insulin resistance. Impact on vascular smooth muscle cells, blood pressure, and lipids.
Topics: Animals; Blood Pressure; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Muscle, Smooth, Vascular; Thiazoles | 1997 |
[Oral hypoglycemic agents--overview].
Topics: Acarbose; Administration, Oral; Biguanides; Chromans; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin Resistance; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Trisaccharides; Troglitazone | 1997 |
[Measures to meet the side effects of the orally administered antihyperglycemic drugs].
Topics: Acarbose; Administration, Oral; Animals; Biguanides; Cardiovascular System; Chromans; Drug Interactions; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Inositol; Insulin Resistance; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Trisaccharides; Troglitazone | 1997 |
[Preclinical studies of pioglitazone (AD-4833)].
Topics: Animals; Diabetes Mellitus; Disease Models, Animal; Glycogen; Glycolysis; Hypoglycemic Agents; Insulin Resistance; Liver; Pioglitazone; Thiazoles; Thiazolidinediones | 1997 |
[Clinical efficacy of Pioglitazone (AD-4833)].
Topics: Blood Glucose; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Pioglitazone; Thiazoles; Thiazolidinediones | 1997 |
[Alpha-glucosidase inhibitor and insulin sensitizer combination therapy in NIDDM].
Topics: Acarbose; Animals; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin Resistance; Pioglitazone; Thiazoles; Thiazolidinediones; Trisaccharides; Troglitazone | 1997 |
Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
Topics: Animals; Chromans; Clinical Trials as Topic; Diabetes Mellitus; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
[Thiazolidindiones in type II diabetes mellitus].
Topics: Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Hypoglycemic Agents; Insulin Resistance; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.
Topics: Adipocytes; Adipose Tissue; Animals; Cell Differentiation; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Ligands; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors | 1998 |
[New drugs against insulin resistance].
Topics: Clinical Trials as Topic; Humans; Hypoglycemic Agents; Insulin Resistance; Thiazoles | 1998 |
Learning to use troglitazone.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Thiazolidinediones--tools for the research of metabolic syndrome X.
Topics: Antioxidants; Blood Vessels; Chromans; Humans; Hypoglycemic Agents; Insulin Resistance; Microvascular Angina; Thiazoles; Thiazolidinediones; Troglitazone; Vasodilator Agents | 1998 |
New therapeutic approaches to reversing insulin resistance.
Topics: Animals; Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Thiazoles; Thiazolidinediones; Troglitazone; Vasodilator Agents | 1998 |
Insulin resistance syndrome: options for treatment.
Topics: Arteriosclerosis; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Microvascular Angina; Obesity; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Insulin resistance: site of the primary defect or how the current and the emerging therapies work.
Topics: Adipose Tissue; Appetite Depressants; Diabetes Mellitus, Type 2; Female; Fenfluramine; Humans; Hypoglycemic Agents; Imidazoles; Insulin Resistance; Ligands; Metformin; Thiazoles; Thiazolidinediones | 1998 |
Insulin signaling in the arterial wall.
Topics: Animals; Arteries; Cell Movement; Endothelium, Vascular; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Signal Transduction; Thiazoles; Thiazolidinediones | 1999 |
Troglitazone. Is it all over?
Topics: Animals; Blood Glucose; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypertriglyceridemia; Hypoglycemic Agents; Insulin Resistance; Liver Function Tests; Male; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
[Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs].
Topics: Administration, Oral; Chromans; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exercise; Fenfluramine; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Lactones; Lipase; Metformin; Orlistat; Peroxisome Proliferators; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes.
Topics: Administration, Oral; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
[Insulin resistance: therapeutic approaches].
Topics: Combined Modality Therapy; Diabetes Mellitus, Type 2; Exercise Therapy; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Metformin; Thiazoles | 1999 |
Three-dimensional quantitative structure-activity relationships (3D-QSAR) of antidiabetic thiazolidinediones.
Topics: Humans; Hypoglycemic Agents; In Vitro Techniques; Insulin Resistance; Models, Chemical; Molecular Structure; Peroxisome Proliferators; Solubility; Statistics as Topic; Structure-Activity Relationship; Thiazoles | 1999 |
A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering.
Topics: Antioxidants; Blood Coagulation; Cardiovascular Diseases; Cardiovascular System; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Metformin; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Clinical efficacy of metformin against insulin resistance parameters: sinking the iceberg.
Topics: Animals; Blood Glucose; Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Leptin; Male; Metformin; Rats; Risk Factors; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
[Etiology and therapy of insulin resistance].
Topics: Animals; Arteriosclerosis; Biguanides; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension; Insulin Resistance; Life Style; Obesity; Risk Factors; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha | 1999 |
New drugs for diabetes.
Topics: Carbamates; Chromans; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Nateglinide; Phenylalanine; Piperidines; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
[Physiological function of peroxisome proliferator-activated receptor].
Topics: Animals; Blood Cells; Cell Differentiation; Cell Division; Colonic Neoplasms; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Ligands; Lipoprotein Lipase; Obesity; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic | 1999 |
[Insulin resistance and cytokine, cytokine receptor].
Topics: Adipocytes; Animals; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Obesity; Receptors, Tumor Necrosis Factor; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2000 |
[The development of thiazolidinedione drugs as anti-diabetic agents].
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Mice; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects].
Topics: Animals; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2000 |
[Proper usage of thiazolidinediones].
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Liver Failure, Acute; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Troglitazone].
Topics: Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Rosiglitazone (BRL-49653)].
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2000 |
[Insulin sensitizer and hypertension].
Topics: Animals; Cholesterol, HDL; Cholesterol, LDL; Chromans; Humans; Hyperinsulinism; Hypertension; Hypoglycemic Agents; Insulin Resistance; Rats; Syndrome; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Diabetes mellitus].
Topics: Blood Coagulation; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 2000 |
[Obesity, insulin resistance and the implication of thiazolidinediones].
Topics: Adipose Tissue; Diabetes Mellitus; Fatty Acids, Nonesterified; Humans; Hypoglycemic Agents; Insulin Resistance; Obesity; Pioglitazone; Receptor, Insulin; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2000 |
[Dyslipidemia in insulin resistance and its improvement by troglitazone].
Topics: Cholesterol, HDL; Chromans; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Insulin sensitizer and urate metabolism].
Topics: Chromans; Diabetes Mellitus, Type 2; Female; Glucose; Gout; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Male; Obesity; Syndrome; Thiazoles; Thiazolidinediones; Troglitazone; Uric Acid | 2000 |
[Cardiovascular effects of the thiazolidinedione troglitazone].
Topics: Animals; Arteriosclerosis; Cardiovascular Diseases; Cardiovascular System; Chromans; Diabetes Mellitus, Type 2; Humans; Hyperinsulinism; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Risk Factors; Syndrome; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Kidney disease and insulin resistance--clinical impact of thiazolidinedione compounds for kidney disease].
Topics: Animals; Chromans; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Kidney Diseases; Protein Kinase C; Rats; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Chronic liver diseases].
Topics: Chronic Disease; Contraindications; Diabetes Mellitus; Humans; Insulin Resistance; Liver; Liver Cirrhosis; Thiazoles; Thiazolidinediones | 2000 |
[Troglitazone for treatment of polycystic ovary syndrome].
Topics: Chromans; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Polycystic Ovary Syndrome; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Insulin resistance induced by drugs or agents].
Topics: Animals; Antihypertensive Agents; Benzothiadiazines; Chromans; Contraceptives, Oral; Diuretics; Glucocorticoids; Humans; Hypoglycemic Agents; Insulin Resistance; Niacin; Rats; Sodium Chloride Symporter Inhibitors; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Thiazolidinediones].
Topics: Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
New agents for Type 2 diabetes.
Topics: Anti-Obesity Agents; Carbamates; Chromans; Diabetes Mellitus, Type 2; Drug Design; Humans; Hypoglycemic Agents; Insulin Resistance; Piperidines; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
[PPAR gamma and thiozolidinedione derivatives as an antidiabetic drug for treating insuline resistance].
Topics: Animals; Chromans; Drug Design; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2000 |
[Hypoglycemic agents to improve insulin resistance].
Topics: Adipocytes; Animals; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Hyperglycemia; Hyperinsulinism; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Obesity; Pioglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Potential new treatments for type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Islets of Langerhans; Thiazoles; Thiazolidinediones | 2000 |
Thiazolidinediones, dyslipidaemia and insulin resistance syndrome.
Topics: Chromans; Clinical Trials as Topic; Glucose; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Phenotype; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists.
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Islets of Langerhans; Mice; Mice, Knockout; Models, Biological; Mutation; Obesity; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2000 |
Insulin-lowering medications in polycystic ovary syndrome.
Topics: Diazoxide; Female; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Menstruation Disturbances; Metformin; Polycystic Ovary Syndrome; Thiazoles; Thiazolidinediones | 2000 |
[Insulin-sensitizing agents and hypertension].
Topics: Animals; Chromans; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Insulin sensitiser drugs.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Thiazoles | 2000 |
Troglitazone and related compounds: therapeutic potential beyond diabetes.
Topics: Animals; Antioxidants; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Microvascular Angina; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2000 |
[Glitazones (thiazolidinedione)].
Topics: Animals; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Gluconeogenesis; Humans; Hypoglycemic Agents; Insulin Resistance; Rats; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2000 |
Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus?
Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Risk Factors; Thiazoles | 2000 |
New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
Topics: Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 2001 |
Nonhypoglycemic effects of thiazolidinediones.
Topics: Body Weight; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Hemostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Liver Failure; Oxidation-Reduction; Pancreas; Polycystic Ovary Syndrome; Risk Factors; Thiazoles | 2001 |
[The importance of syndrome X in daily practice].
Topics: Anthropometry; Cardiovascular Diseases; Diet, Reducing; Exercise; Humans; Hyperinsulinism; Hypertension; Hypertriglyceridemia; Hypoglycemic Agents; Insulin Resistance; Lipoproteins, HDL; Lipoproteins, LDL; Obesity; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
The association between insulin resistance and endotheliopathy.
Topics: Diabetes Mellitus, Type 2; Endothelium, Vascular; Humans; Hyperglycemia; Hyperlipidemias; Hypertension; Insulin Resistance; Syndrome; Thiazoles; Vasodilation | 1999 |
Promising new approaches.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Obesity; Thiazoles; Weight Loss | 1999 |
The polycystic ovary syndrome: treatment with insulin sensitizing agents.
Topics: Chromans; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Obesity; Ovary; Polycystic Ovary Syndrome; Signal Transduction; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Insulin resistance and its treatment by thiazolidinediones.
Topics: Adipose Tissue; Binding Sites; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dimerization; Drug Interactions; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Male; Models, Biological; Muscle, Smooth; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sex Factors; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
Using thiazolidinediones: rosiglitazone and pioglitazone in clinical practice.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Education, Continuing; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Pioglitazone; Polycystic Ovary Syndrome; Thiazoles; Thiazolidinediones; United States | 2001 |
[Lipodystrophia].
Topics: Animals; Cardiomyopathy, Hypertrophic; Chromans; Diabetes Mellitus; Diagnosis, Differential; Fatty Liver; Humans; Hyperinsulinism; Hypertriglyceridemia; Insulin Resistance; Insulin-Like Growth Factor I; Lipid Metabolism; Lipodystrophy; Prognosis; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
[Significance of PPAR gamma (peroxisome proliferator-activated receptor gamma) in atherosclerosis].
Topics: Animals; Arteriosclerosis; Cell Differentiation; Humans; Insulin Resistance; Ligands; Lipoproteins, LDL; Macrophages; Mice; Muscle, Smooth, Vascular; Rats; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
[Insulin resistance-reducing effect of a new thiazolidinedione derivative, pioglitazone].
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Humans; Hypoglycemic Agents; Insulin Resistance; Mice; Pioglitazone; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones | 2001 |
Obesity and free fatty acids: double trouble.
Topics: Chylomicrons; Coronary Artery Disease; Fatty Acids, Nonesterified; Humans; Hyperglycemia; Hyperlipidemias; Insulin Resistance; Lipid Metabolism; Lipoproteins, VLDL; Liver; Obesity; Postprandial Period; Risk Factors; Thiazoles; Thiazolidinediones; Weight Loss | 2001 |
[Insulin resistance: why is it important to treat?].
Topics: Adipose Tissue; Blood Glucose; Coronary Disease; Diabetes Mellitus, Type 2; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Muscles; Syndrome; Thiazoles | 2001 |
[Mechanisms of action of thiazolidinediones].
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Gene Expression; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Muscle, Skeletal; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors | 2001 |
Triglycerides, fatty acids and insulin resistance--hyperinsulinemia.
Topics: Adipose Tissue; Animals; Fatty Acids; Humans; Hyperinsulinism; Insulin; Insulin Resistance; Lipolysis; Muscle, Skeletal; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors; Triglycerides | 2001 |
Current views on the mechanism of action of thiazolidinedione insulin sensitizers.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Models, Biological; Thiazoles | 1999 |
Actos (pioglitazone): a new treatment for type 2 diabetes.
Topics: Adult; Aged; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Pioglitazone; Randomized Controlled Trials as Topic; Thiazoles; Thiazolidinediones; Triglycerides | 2001 |
[The thiazolidinedione derivates: a new class of oral blood glucose lowering agents].
Topics: Administration, Oral; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
[Objectives and therapeutic strategy in type 2 diabetes mellitus].
Topics: Carbamates; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Piperidines; Thiazoles | 2001 |
PPARS, insulin resistance and type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors | 2001 |
[Antidiabetic effect of thiazolidinediones].
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Glucose; Humans; Insulin Resistance; Muscle, Skeletal; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors | 2001 |
Pioglitazone: mechanism of action.
Topics: Blood Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Nuclear Proteins; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
Insulin resistance and insulin sensitizers.
Topics: Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension; Insulin; Insulin Resistance; Insulin Secretion; Thiazoles | 2001 |
Beta-cell deterioration--prospects for reversal or prevention.
Topics: Animals; Blood Glucose; Cell Death; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Islets of Langerhans; Lipids; Rats; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
Insulin resistance and beta-cell function--a clinical perspective.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
PPAR gamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
[Insulin sensitizer drugs, thiazolidinediones: current state and prospect].
Topics: Adipocytes; Animals; Blood Glucose; Depression, Chemical; Diabetes Mellitus, Type 2; Drug Design; Fatty Acids, Nonesterified; Humans; Insulin; Insulin Resistance; Insulin Secretion; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2001 |
[A trend of insulin sensitizer which is under development].
Topics: Animals; Benzoates; Biphenyl Compounds; Clinical Trials as Topic; Drug Design; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
[Pharmacological effects of a thiazolidinedione derivative, pioglitazone].
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2001 |
[Evaluation of a thiazolidinedione compound as a new antidiabetic drug].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
[Clinical difference between thiazolidinediones and biguanides].
Topics: Biguanides; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Thiazoles; Thiazolidinediones | 2001 |
[Thiazolidinediones--a new class of oral antidiabetics].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Receptors, Cytoplasmic and Nuclear; Thiazoles | 2001 |
[Free fatty acids: mediators of insulin resistance and atherosclerosis].
Topics: Arteriosclerosis; Complement C3; Fatty Acids, Nonesterified; Humans; Insulin Resistance; Lipoproteins; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors; Triglycerides | 2002 |
Pharmacological treatment of insulin resistance in obesity.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Hypoglycemic Agents; Insulin Resistance; Obesity; Rats; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
[Recent progress in therapy of diabetes mellitus].
Topics: Blood Glucose; Diabetes Mellitus; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin Resistance; Reference Standards; Sulfonylurea Compounds; Thiazoles | 2001 |
[Polycystic ovary syndrome: treatment with insulin-sensitizing agents].
Topics: Androgens; Chromans; Female; Hirsutism; Humans; Hypoglycemic Agents; Insulin Resistance; Luteinizing Hormone; Metformin; Ovulation; Polycystic Ovary Syndrome; Pregnancy; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Current treatment of insulin resistance in type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Thiazoles; Thiazolidinediones | 2000 |
Polycystic ovary syndrome. Long term sequelae and management.
Topics: Adult; Blood Glucose; Cardiovascular Diseases; Contraceptives, Oral; Diabetes Mellitus, Type 2; Diagnosis, Differential; Endometrial Neoplasms; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Polycystic Ovary Syndrome; Pregnancy; Progestins; Randomized Controlled Trials as Topic; Risk Factors; Thiazoles; Thiazolidinediones | 2002 |
New solutions for type 2 diabetes mellitus: the role of pioglitazone.
Topics: Diabetes Mellitus, Type 2; Glycated Hemoglobin; Half-Life; Humans; Hypoglycemic Agents; Insulin Resistance; Intestinal Absorption; Pioglitazone; Randomized Controlled Trials as Topic; Thiazoles; Thiazolidinediones | 2002 |
[PPARgamma and insulin resistance].
Topics: Adipose Tissue; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Muscle, Skeletal; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
[Glitazones and weight gain].
Topics: Adipose Tissue; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Risk Factors; Thiazoles; Thiazolidinediones; Weight Gain | 2002 |
[Against insulin resistance. Insulin sensitizers].
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
[Medication of the month. Rosiglitazone (Avandia)].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Prognosis; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Weight Gain | 2002 |
Impaired ('diabetic') insulin signaling and action occur in fat cells long before glucose intolerance--is insulin resistance initiated in the adipose tissue?
Topics: Adipocytes; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Intracellular Signaling Peptides and Proteins; Phosphoproteins; Signal Transduction; Thiazoles; Thiazolidinediones | 2002 |
PPARgamma and the thiazolidinediones: molecular basis for a treatment of 'Syndrome X'?
Topics: Animals; Humans; Insulin Resistance; Metabolic Syndrome; Microbodies; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors | 2002 |
New oral thiazolidinedione antidiabetic agents act as insulin sensitizers.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Pioglitazone; Thiazoles; Thiazolidinediones | 1992 |
56 trial(s) available for thiazoles and Insulin Sensitivity
| Article | Year |
|---|---|
Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity.
Topics: Acetanilides; Adipose Tissue, Brown; Adolescent; Adult; Apolipoprotein A-I; Biomarkers; Cholesterol, HDL; Female; Humans; Insulin Resistance; Positron Emission Tomography Computed Tomography; Thiazoles; Urinary Bladder, Overactive | 2020 |
Changes in Visceral and Subcutaneous Fat in Youth With Type 2 Diabetes in the TODAY Study.
Topics: Adiposity; Adolescent; Blood Glucose; Body Fat Distribution; Child; Combined Modality Therapy; Diabetes Mellitus, Type 2; Drug Combinations; Exercise Therapy; Female; Humans; Insulin Resistance; Intra-Abdominal Fat; Life Style; Male; Metformin; Obesity; Sex Factors; Subcutaneous Fat; Thiazoles | 2019 |
Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY.
Topics: Adolescent; Child; Diabetes Mellitus, Type 2; Drug Combinations; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Life Style; Male; Metformin; Thiazoles | 2013 |
METFORMIN-SUSTAINED WEIGHT LOSS AND REDUCED ANDROID FAT TISSUE AT 12 MONTHS IN EMPOWIR (ENHANCE THE METABOLIC PROFILE OF WOMEN WITH INSULIN RESISTANCE): A DOUBLE BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL OF NORMOGLYCEMIC WOMEN WITH MIDLIFE WEIGHT GAIN.
Topics: Adipose Tissue; Adult; Aging; Body Fat Distribution; Climacteric; Double-Blind Method; Drug Combinations; Female; Humans; Insulin Resistance; Metformin; Middle Aged; Obesity; Overweight; Placebos; Thiazoles; Weight Gain; Weight Loss | 2016 |
Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Chronic Disease; Clozapine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hyperglycemia; Insulin Resistance; Male; Middle Aged; Morbidity; Olanzapine; Piperazines; Schizophrenia; Thiazoles; Time Factors | 2009 |
Discordant effects on central obesity, hepatic insulin resistance, and alanine aminotransferase of low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance.
Topics: Alanine Transaminase; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Fatty Liver; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Metformin; Obesity, Abdominal; Thiazoles; Waist-Hip Ratio | 2012 |
[Effect of rosiglitazone on insulin resistance and hyperandrogenism in polycystic ovary syndrome].
Topics: Administration, Oral; Adult; Androstenedione; Blood Glucose; Body Weight; Female; Follicle Stimulating Hormone; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin; Insulin Resistance; Leptin; Lipids; Luteinizing Hormone; Menstruation; Neuropeptide Y; Ovulation; Polycystic Ovary Syndrome; Rosiglitazone; Testosterone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women.
Topics: Adult; Chromans; Diabetes Mellitus, Type 2; Diabetes, Gestational; Double-Blind Method; Female; Glucose Tolerance Test; Hispanic or Latino; Humans; Incidence; Insulin; Insulin Resistance; Islets of Langerhans; Medical Records; Pregnancy; Risk Factors; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Troglitazone antagonizes metabolic effects of glucocorticoids in humans: effects on glucose tolerance, insulin sensitivity, suppression of free fatty acids, and leptin.
Topics: Adult; Chromans; Dexamethasone; Drug Interactions; Energy Metabolism; Fatty Acids, Nonesterified; Female; Glucocorticoids; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin Resistance; Leptin; Male; Middle Aged; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.
Topics: Adiponectin; Adult; Animals; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Lipids; Male; Middle Aged; Obesity; Proteins; Rats; Thiazoles; Thiazolidinediones | 2002 |
Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study.
Topics: Adipose Tissue; Adult; Blood Glucose; Body Composition; Female; Glucose; Glucose Clamp Technique; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Pilot Projects; Radiography; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients.
Topics: Aged; Blood Glucose; Blood Pressure; Female; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Clinical evaluation of pioglitazone in patients with type 2 diabetes using alpha-glucosidase inhibitor and examination of its efficacy profile.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin Resistance; Leptin; Lipids; Male; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Treatment Failure; Treatment Outcome | 2003 |
Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome.
Topics: Blood Glucose; Blood Pressure; Chromans; Endothelium, Vascular; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Obesity; Plasminogen Activator Inhibitor 1; Polycystic Ovary Syndrome; Regional Blood Flow; Testosterone; Thiazoles; Thiazolidinediones; Troglitazone; Vasodilation | 2003 |
Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy.
Topics: Adult; Area Under Curve; Clomiphene; Drug Therapy, Combination; Estrogen Antagonists; Female; Follicle Stimulating Hormone; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Luteinizing Hormone; Menstruation; Polycystic Ovary Syndrome; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Blood Glucose; Clomiphene; Deamino Arginine Vasopressin; Dehydroepiandrosterone Sulfate; Double-Blind Method; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Ovulation Induction; Placebos; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Outcome; Rosiglitazone; Sex Hormone-Binding Globulin; Testosterone; Thiazoles; Thiazolidinediones | 2003 |
Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.
Topics: Adult; Apolipoproteins B; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glycated Hemoglobin; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 2003 |
Usefulness of troglitazone administration to obese hyperglycaemic patients with near-normoglycaemia.
Topics: Adult; Aged; Blood Glucose; Chromans; Deoxyglucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Obesity; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
Long-term cardiovascular effects of insulin sensitizer troglitazone on non-diabetic individuals with insulin resistance: double blind, prospective randomized study.
Topics: Adult; Aorta; Blood Flow Velocity; Blood Pressure; Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Middle Aged; Prospective Studies; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke.
Topics: Aged; Blood Glucose; Brain Ischemia; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Ischemic Attack, Transient; Male; Patient Compliance; Pioglitazone; Risk Factors; Stroke; Thiazoles; Thiazolidinediones; Treatment Outcome | 2003 |
Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome.
Topics: Adrenal Glands; Adult; Blood Glucose; Chromans; Dehydroepiandrosterone Sulfate; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucose Tolerance Test; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Polycystic Ovary Syndrome; Prospective Studies; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Exercise; Fatty Acids, Nonesterified; Female; Glucose Intolerance; Glucose Transporter Type 4; Humans; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Isoenzymes; Male; Middle Aged; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Phosphatidylinositol 3-Kinases; Phosphatidylinositol Phosphates; Phosphoproteins; Phosphorylation; Protein Kinase C; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones | 2003 |
The impact of an insulin sensitizer, troglitazone, on glucose metabolism in African Americans at risk for type 2 diabetes mellitus: a placebo-controlled, 24-month randomized study.
Topics: Adult; Black People; Blood Glucose; Body Constitution; Body Mass Index; C-Peptide; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Genetic Predisposition to Disease; Glucose Intolerance; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Placebos; Skinfold Thickness; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.
Topics: Adult; Aged; Alanine Transaminase; Biopsy; Fatty Liver; Female; Humans; Insulin Resistance; Liver; Male; Middle Aged; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Improvement in glycaemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Metformin; Middle Aged; Thiazoles; Treatment Outcome | 2006 |
Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Metformin; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2006 |
Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.
Topics: Aged; Blood Glucose; Blood Pressure; Chromans; Diabetes Mellitus, Type 2; Female; Heart Rate; Hemoglobin A; Humans; Hypertension; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Renin; Single-Blind Method; Thiazoles; Thiazolidinediones; Troglitazone | 1995 |
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tolerance Test; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Obesity; Thiazoles; Thiazolidinediones; Troglitazone | 1994 |
Metabolic effects of darglitazone, an insulin sensitizer, in NIDDM subjects.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Obesity; Thiazoles; Thiazolidinediones | 1995 |
The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.
Topics: Adult; Body Mass Index; Chromans; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Double-Blind Method; Estradiol; Estrone; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Polycystic Ovary Syndrome; Regression Analysis; Testosterone; Thiazoles; Thiazolidinediones; Troglitazone | 1996 |
Leptin concentrations in the polycystic ovary syndrome.
Topics: Adult; Body Mass Index; Chromans; Double-Blind Method; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Leptin; Obesity; Osmolar Concentration; Polycystic Ovary Syndrome; Proteins; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Efficacy of troglitazone measured by insulin resistance index.
Topics: Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 1997 |
Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
Topics: Administration, Oral; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Middle Aged; Potassium; Risk Factors; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Analysis of Variance; Blood Glucose; C-Peptide; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Middle Aged; Placebos; Regression Analysis; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Male; Middle Aged; Regression Analysis; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan.
Topics: Administration, Oral; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones | 1997 |
Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects.
Topics: Adult; Blood Glucose; Body Weight; Cholesterol, LDL; Chromans; Cross-Over Studies; Double-Blind Method; Fasting; Female; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Peroxidation; Lipids; Male; Obesity; Oxidation-Reduction; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone.
Topics: Acetylcholine; Adult; Analysis of Variance; Biomarkers; Blood Glucose; Cardiovascular System; Case-Control Studies; Chromans; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Endothelium, Vascular; Enzyme Inhibitors; Fasting; Female; Forearm; Glucose Clamp Technique; Hemodynamics; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Middle Aged; Nitroprusside; Obesity; omega-N-Methylarginine; Reference Values; Regional Blood Flow; Thiazoles; Thiazolidinediones; Troglitazone; Vasodilation; Vasodilator Agents | 1998 |
Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients.
Topics: Blood Glucose; Body Mass Index; Chromans; Diabetes Mellitus, Type 2; Energy Intake; Feeding Behavior; Glycated Hemoglobin; Humans; Hunger; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Leptin; Lipids; Middle Aged; Proteins; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
Topics: Aged; Aged, 80 and over; Alanine Transaminase; Aspartate Aminotransferases; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Fasting; Fatigue; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone; Vomiting | 1998 |
Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. AD-4833 Clamp-OGL Study Group.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones | 1998 |
Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome.
Topics: Adult; Androgens; Chromans; Female; Gonadotropins; Hormones; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Ovulation; Polycystic Ovary Syndrome; Prospective Studies; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Cardiovascular Diseases; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Energy Intake; Exercise Therapy; Female; Glucose Tolerance Test; Health Policy; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Life Style; Liver; Male; Metformin; Middle Aged; Obesity; Outcome and Process Assessment, Health Care; Quality of Life; Research Design; Risk Factors; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance.
Topics: Aged; Chromans; Coronary Disease; Female; Follow-Up Studies; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin Resistance; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Phenotype; Probability; Reference Values; Thiazoles; Thiazolidinediones; Treatment Outcome; Triglycerides; Troglitazone | 1999 |
Effect of troglitazone on lipoprotein(a) levels in obese subjects.
Topics: Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Agents; Insulin Resistance; Lipoprotein(a); Obesity; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Lack of effects of the beta3-adrenoreceptor agonist UL-TG 307 on insulin sensitivity and insulin secretion in Type 2 diabetic patients.
Topics: Adrenergic beta-Agonists; Adult; Body Weight; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Glycerol; Humans; Insulin; Insulin Resistance; Insulin Secretion; Lipids; Male; Middle Aged; Thiazoles | 1999 |
Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus.
Topics: Adipose Tissue; Adult; Anti-HIV Agents; Blood Glucose; Body Weight; Chromans; Diabetes Mellitus; HIV Infections; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Middle Aged; Pilot Projects; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes.
Topics: Adipose Tissue; Adult; Aged; Body Composition; Chemical and Drug Induced Liver Injury; Child; Chromans; Drug Administration Schedule; Fatty Acids, Nonesterified; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipodystrophy; Liver; Male; Middle Aged; Prospective Studies; Respiratory Function Tests; Statistics, Nonparametric; Syndrome; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 2000 |
Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; C-Peptide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Middle Aged; Placebos; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 2001 |
Gonadotropins at menopause: the influence of obesity, insulin resistance, and estrogens.
Topics: Chromans; Clomiphene; Estrogens; Feedback, Physiological; Female; Follicle Stimulating Hormone; Gonadotropins; Humans; Hypoglycemic Agents; Insulin Resistance; Menopause; Metformin; Middle Aged; Obesity; Pregnancy; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Beneficial effect of troglitazone, an insulin-sensitizing antidiabetic agent, on coronary circulation in patients with non-insulin-dependent diabetes mellitus.
Topics: Adenosine Triphosphate; Aged; Blood Glucose; Case-Control Studies; Chromans; Coronary Circulation; Diabetes Mellitus, Type 2; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Thallium Radioisotopes; Thiazoles; Thiazolidinediones; Troglitazone; Vasodilator Agents | 2001 |
Serum leptin level as an indicator to predict the clinical efficacy of troglitazone in patients with type 2 diabetes mellitus.
Topics: Biomarkers; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Leptin; Male; Middle Aged; Models, Biological; Predictive Value of Tests; Regression Analysis; Thiazoles; Thiazolidinediones; Time Factors; Troglitazone | 2001 |
The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Arteriosclerosis; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Endpoint Determination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Resistance; Islets of Langerhans; Lipids; Lipoproteins; Male; Middle Aged; Pioglitazone; Single-Blind Method; Thiazoles; Thiazolidinediones; Treatment Outcome; United States | 2001 |
Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d: effects on the very-low-density and high-density lipoprotein particle distribution.
Topics: Aged; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fatty Acids, Nonesterified; Female; Fibrinogen; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Lipoproteins; Lipoproteins, HDL; Lipoproteins, VLDL; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization.
Topics: 3T3 Cells; Adipocytes; Adiponectin; Animals; Blood Proteins; Cross-Over Studies; Diabetes Mellitus, Type 2; Electrophoresis, Polyacrylamide Gel; Hypoglycemic Agents; Insulin; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Male; Metformin; Mice; Mice, Inbred C57BL; Pilot Projects; Proteins; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
Topics: Adult; Aged; Analysis of Variance; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 2002 |
282 other study(ies) available for thiazoles and Insulin Sensitivity
| Article | Year |
|---|---|
Effects of chronic mirabegron treatment on metabolic and cardiovascular parameters as well as on atherosclerotic lesions of WHHL rabbits with high-fructose high-fat diet-induced insulin resistance.
Topics: Acetanilides; Animals; Atherosclerosis; Blood Glucose; Diet, High-Fat; Fructose; Insulin; Insulin Resistance; Rabbits; Thiazoles | 2022 |
Complementary Immunometabolic Effects of Exercise and PPARβ/δ Agonist in the Context of Diet-Induced Weight Loss in Obese Female Mice.
Topics: Animals; Diet, High-Fat; Energy Metabolism; Female; Glucose; Insulin Resistance; Lipid Metabolism; Lymphocyte Count; Mice; Mice, Obese; Muscle, Skeletal; Obesity; Physical Conditioning, Animal; PPAR delta; PPAR-beta; T-Lymphocytes, Regulatory; Thiazoles; Weight Loss | 2019 |
A Novel TNF-α Converting Enzyme (TACE) Selective Inhibitor JTP-96193 Prevents Insulin Resistance in KK-A
Topics: ADAM17 Protein; Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Rats; Rats, Inbred Lew; Thiazoles; Tumor Necrosis Factor-alpha | 2019 |
The Effects of RKI-1447 in a Mouse Model of Nonalcoholic Fatty Liver Disease Induced by a High-Fat Diet and in HepG2 Human Hepatocellular Carcinoma Cells Treated with Oleic Acid.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Carcinoma, Hepatocellular; Cholesterol; Diet, High-Fat; Disease Models, Animal; Glucose Tolerance Test; Hep G2 Cells; Humans; Insulin Resistance; Interleukin-6; Liver; Liver Neoplasms; Male; Malondialdehyde; Mice, Inbred ICR; Models, Biological; Non-alcoholic Fatty Liver Disease; Oleic Acid; Oxidative Stress; rhoA GTP-Binding Protein; Signal Transduction; Superoxide Dismutase; Thiazoles; Triglycerides; Tumor Necrosis Factor-alpha; Urea | 2020 |
Might β3-adrenergic receptor agonists be useful in disorders of glucose homeostasis?
Topics: Acetanilides; Adipose Tissue, Brown; Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Cholesterol, HDL; Glucose; Homeostasis; Humans; Insulin Resistance; Thiazoles | 2020 |
Enhancing insulin sensitivity by dual PPARγ partial agonist, β-catenin inhibitor: Design, synthesis of new αphthalimido-o-toluoyl2-aminothiazole hybrids.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Adiponectin; Animals; beta Catenin; Cell Differentiation; Diabetes Mellitus, Type 2; Gene Expression; Glucose; Insulin; Insulin Resistance; Mice; Molecular Docking Simulation; Phthalimides; PPAR gamma; Rosiglitazone; Thiazoles; Thiazolidinediones | 2020 |
Pioglitazone does not synergize with mirabegron to increase beige fat or further improve glucose metabolism.
Topics: Acetanilides; Adipose Tissue, Beige; Drug Synergism; Female; Glucose; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Obesity; Pioglitazone; Thiazoles | 2021 |
Addressing the role of 11β-hydroxysteroid dehydrogenase type 1 in the development of polycystic ovary syndrome and the putative therapeutic effects of its selective inhibition in a preclinical model.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Cells, Cultured; Disease Models, Animal; Drug Evaluation, Preclinical; Enzyme Inhibitors; Female; Humans; Infertility, Female; Insulin Resistance; Ovary; Piperazines; Polycystic Ovary Syndrome; Rats; Rats, Sprague-Dawley; Sulfonamides; Thiazoles | 2021 |
"2-(4-Fluorobenzamido)-4-methylthiazole-5-carboxylic acid" a novel thiazole compound, ameliorates insulin sensitivity and hyperlipidaemia in streptozotocin-induced diabetic rats: Plausible role of inflammatory and oxidative stress markers.
Topics: Animals; Benzamides; Biomarkers; Blood Glucose; Body Weight; Cytokines; Diabetes Mellitus, Experimental; Drinking; Feeding Behavior; Glucose Intolerance; Glycated Hemoglobin; Hyperlipidemias; Inflammation; Inflammation Mediators; Insulin; Insulin Resistance; Kidney; Lipids; Liver; Organ Size; Oxidative Stress; Pancreas; Rats, Wistar; Streptozocin; Thiazoles; Toxicity Tests, Acute | 2017 |
Evaluation of 4-methyl-2-[(2-methylbenzyl) amino]-1,3-thiazole-5-carboxylic acid against hyperglycemia, insulin sensitivity, and oxidative stress-induced inflammatory responses and β-cell damage in the pancreas of streptozotocin-induced diabetic rats.
Topics: Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glycated Hemoglobin; Hypoglycemic Agents; Inflammation Mediators; Insulin; Insulin Resistance; Insulin-Secreting Cells; Interleukin-6; Oxidative Stress; Rats, Wistar; Streptozocin; Thiazoles; Tumor Necrosis Factor-alpha | 2018 |
Ligand-Dependent Interaction of PPARδ With T-Cell Protein Tyrosine Phosphatase 45 Enhances Insulin Signaling.
Topics: Active Transport, Cell Nucleus; Adipocytes, White; Alternative Splicing; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Cells, Cultured; Glucose Intolerance; Hepatocytes; Humans; Insulin Resistance; Male; Mice, Inbred ICR; Muscle Fibers, Skeletal; Obesity; PPAR delta; Protein Multimerization; Protein Tyrosine Phosphatase, Non-Receptor Type 2; Recombinant Fusion Proteins; RNA Interference; Specific Pathogen-Free Organisms; Thiazoles | 2018 |
Midlife insulin resistance,
Topics: Aged; Aging; Amyloid; Aniline Compounds; Apolipoprotein E4; Brain; Cross-Sectional Studies; Female; Follow-Up Studies; Genotype; Heterozygote; Humans; Insulin Resistance; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Thiazoles | 2018 |
GW0742 (PPAR-beta agonist) attenuates hepatic endoplasmic reticulum stress by improving hepatic energy metabolism in high-fat diet fed mice.
Topics: Alanine Transaminase; Animals; Apoptosis; Body Weight; Cholesterol; Diet, High-Fat; Endoplasmic Reticulum Stress; Energy Intake; Energy Metabolism; Fatty Liver; Feeding Behavior; Glucose Tolerance Test; Hepatocytes; Inflammation; Insulin Resistance; Lipogenesis; Liver; Male; Mice, Inbred C57BL; Oxidation-Reduction; PPAR-beta; Protein Isoforms; Thiazoles | 2018 |
PPARβ/δ agonist GW501516 inhibits TNFα-induced repression of adiponectin and insulin receptor in 3T3-L1 adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Animals; Insulin Resistance; Mice; PPAR delta; PPAR-beta; Receptor, Insulin; Thiazoles; Tumor Necrosis Factor-alpha | 2019 |
Adipose tissue macrophage-derived exosomal miR-29a regulates obesity-associated insulin resistance.
Topics: Adipocytes; Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Exosomes; Gene Knockdown Techniques; Hepatocytes; In Vitro Techniques; Insulin Resistance; Macrophages; Male; Mice; Mice, Inbred C57BL; MicroRNAs; Muscle Cells; Obesity; Receptors, Cytoplasmic and Nuclear; Thiazoles | 2019 |
Azoramide improves mitochondrial dysfunction in palmitate-induced insulin resistant H9c2 cells.
Topics: Adenosine Triphosphate; Amides; Animals; Cell Line; Glucose; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Membrane Potential, Mitochondrial; Mitochondria; Mitochondrial Dynamics; Palmitic Acid; Rats; Reactive Oxygen Species; Signal Transduction; Thiazoles | 2019 |
Azoramide ameliorates fructose-induced nonalcoholic fatty liver disease in mice.
Topics: Amides; Animals; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Fructose; Insulin Resistance; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Thiazoles | 2019 |
High sugar intake and development of skeletal muscle insulin resistance and inflammation in mice: a protective role for PPAR- δ agonism.
Topics: Animals; Carbohydrates; Fibroblast Growth Factors; Gene Expression Regulation; Glucose; Glucose Tolerance Test; Immunohistochemistry; Inflammation; Insulin; Insulin Resistance; Interleukin-6; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Nutritive Sweeteners; PPAR delta; Signal Transduction; Thiazoles | 2013 |
Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore Longitudinal Study of Aging.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Aniline Compounds; Baltimore; Benzothiazoles; Cognition Disorders; Female; Glucose Intolerance; Humans; Insulin Resistance; Longitudinal Studies; Male; Prospective Studies; Radionuclide Imaging; Thiazoles | 2013 |
A small volatile bacterial molecule triggers mitochondrial dysfunction in murine skeletal muscle.
Topics: Acetophenones; Adenosine Triphosphate; Animals; Blotting, Western; Gene Expression Regulation; Humans; Insulin Resistance; Magnetic Resonance Spectroscopy; Metabolomics; Mice; Microarray Analysis; Mitochondrial Diseases; Muscle, Skeletal; Pseudomonas aeruginosa; Quorum Sensing; Tetrazolium Salts; Thiazoles | 2013 |
Peroxisome proliferator-activated receptor δ agonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance, and atherosclerosis in low-density lipoprotein receptor knockout mice.
Topics: Animals; Anti-Inflammatory Agents; Aortitis; Atherosclerosis; Biomarkers; Blood Glucose; Cholesterol, Dietary; Diet, High-Fat; Disease Models, Animal; Dyslipidemias; Inflammation Mediators; Insulin; Insulin Resistance; Lipids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; PPAR delta; Receptors, LDL; Signal Transduction; Thiazoles; Time Factors | 2014 |
Comment on: TODAY Study Group. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY. Diabetes Care 2013;36:1749-1757.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Life Style; Male; Metformin; Thiazoles | 2013 |
Peroxisome proliferator activated receptor-δ: the middle child vies for attention.
Topics: Animals; Anti-Inflammatory Agents; Aortitis; Atherosclerosis; Insulin Resistance; Male; PPAR delta; Receptors, LDL; Thiazoles | 2014 |
Effects of inhibition of serine palmitoyltransferase (SPT) and sphingosine kinase 1 (SphK1) on palmitate induced insulin resistance in L6 myotubes.
Topics: Analysis of Variance; Animals; Blotting, Western; Chromatography, High Pressure Liquid; Deoxyglucose; Fatty Acids, Monounsaturated; Insulin Resistance; Muscle Fibers, Skeletal; Palmitates; Phosphotransferases (Alcohol Group Acceptor); Rats; Serine C-Palmitoyltransferase; Thiazoles | 2013 |
Insulin resistance predicts brain amyloid deposition in late middle-aged adults.
Topics: Aged; Amyloid; Aniline Compounds; Apolipoproteins E; Body Mass Index; Brain; Female; Humans; Hyperglycemia; Imaging, Three-Dimensional; Insulin Resistance; Magnetic Resonance Imaging; Male; Mental Status Schedule; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Thiazoles | 2015 |
An evaluation of the effects of the novel antipsychotic drug lurasidone on glucose tolerance and insulin resistance: a comparison with olanzapine.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Female; Glucose Tolerance Test; Insulin Resistance; Isoindoles; Lurasidone Hydrochloride; Olanzapine; Rats; Rats, Sprague-Dawley; Thiazoles | 2014 |
SIRT1 activation ameliorates hyperglycaemia by inducing a torpor-like state in an obese mouse model of type 2 diabetes.
Topics: Angiopoietin-Like Protein 8; Angiopoietin-like Proteins; Anilides; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Enzyme Activation; Enzyme Activators; Hepatocytes; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Mice, Mutant Strains; Obesity; Peptide Hormones; Signal Transduction; Sirtuin 1; Thiazoles; Time Factors; Torpor | 2015 |
PPARβ/δ ameliorates fructose-induced insulin resistance in adipocytes by preventing Nrf2 activation.
Topics: 3T3-L1 Cells; Adipocytes; Alkaloids; Animals; CD36 Antigens; Cell Line; Cytokines; Fructose; Glucose Intolerance; Humans; Immunoblotting; Insulin Resistance; JNK Mitogen-Activated Protein Kinases; Lipoproteins, LDL; Male; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Knockout; NF-E2-Related Factor 2; PPAR delta; PPAR-beta; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Thiazoles | 2015 |
Short-term administration of GW501516 improves inflammatory state in white adipose tissue and liver damage in high-fructose-fed mice through modulation of the renin-angiotensin system.
Topics: Adipose Tissue, White; Animals; Fructose; Hepatic Stellate Cells; Inflammation; Insulin Resistance; Lipogenesis; Liver; Male; Mice; Mice, Inbred C57BL; PPAR delta; Renin-Angiotensin System; Thiazoles | 2015 |
Chronic peroxisome proliferator-activated receptorβ/δ agonist GW0742 prevents hypertension, vascular inflammatory and oxidative status, and endothelial dysfunction in diet-induced obesity.
Topics: Adiponectin; Adipose Tissue; Animals; Aorta; Blood Glucose; Caveolin 1; Diet, High-Fat; Endothelium, Vascular; Glucose Tolerance Test; Hypertension; Insulin Resistance; Interleukin-6; Male; Mice; Nitric Oxide Synthase Type III; Obesity; PPAR delta; PPAR-beta; Reactive Oxygen Species; Sulfones; Thiazoles; Thiophenes; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha; Vasodilation | 2015 |
Retinoic acid receptor β2 agonists restore glycaemic control in diabetes and reduce steatosis.
Topics: Animals; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diet, High-Fat; Drugs, Investigational; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Kidney; Lipid Peroxidation; Liver; Male; Mice, Inbred C57BL; Mice, Mutant Strains; Muscle, Skeletal; Non-alcoholic Fatty Liver Disease; Obesity; Oxidative Stress; Pancreas; Receptors, Retinoic Acid; Thiazoles | 2016 |
Development of PPAR-agonist GW0742 as antidiabetic drug: study in animals.
Topics: Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Discovery; Fructose; Glucose Transporter Type 4; Homeostasis; Hypoglycemic Agents; Insulin; Insulin Resistance; Intracellular Signaling Peptides and Proteins; Liver; Male; Muscle, Skeletal; Phosphoenolpyruvate Carboxykinase (GTP); PPAR alpha; Rats, Wistar; Streptozocin; Thiazoles; Time Factors | 2015 |
Adiponectin, Insulin Sensitivity, β-Cell Function, and Racial/Ethnic Disparity in Treatment Failure Rates in TODAY.
Topics: Adiponectin; Adolescent; Black People; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; Drug Combinations; Ethnicity; Female; Glucose Tolerance Test; Health Status Disparities; Hispanic or Latino; Humans; Hypoglycemic Agents; Insulin Resistance; Life Style; Male; Metformin; Thiazoles; Treatment Failure; White People | 2017 |
2-[(4-Chlorobenzyl) amino]-4-methyl-1,3-thiazole-5-carboxylic acid exhibits antidiabetic potential and raises insulin sensitivity via amelioration of oxidative enzymes and inflammatory cytokines in streptozotocin-induced diabetic rats.
Topics: Animals; Animals, Newborn; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Glycated Hemoglobin; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Oxidative Stress; Pancreas; Rats; Rats, Wistar; Thiazoles | 2017 |
Peroxisome proliferator-activated receptor delta-agonist, GW501516, ameliorates insulin resistance, improves dyslipidaemia in monosodium L-glutamate metabolic syndrome mice.
Topics: Animals; Animals, Newborn; Blood Glucose; Cholesterol, HDL; Dyslipidemias; Fatty Acids; Gene Expression; Insulin; Insulin Resistance; Leptin; Metabolic Syndrome; Mice; Mice, Obese; Oxidation-Reduction; PPAR delta; Sodium Glutamate; Thiazoles | 2008 |
Evaluation of antioxidant systems (coenzyme Q10 and total antioxidant capacity) in morbid obesity before and after biliopancreatic diversion.
Topics: Adult; Antioxidants; Benzothiazoles; Biliopancreatic Diversion; Blood Glucose; Cholesterol; Female; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Obesity, Morbid; Statistics, Nonparametric; Sulfonic Acids; Thiazoles; Triglycerides; Ubiquinone; Uric Acid | 2008 |
Identification of a new JNK inhibitor targeting the JNK-JIP interaction site.
Topics: Adaptor Proteins, Signal Transducing; Animals; Binding, Competitive; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Experimental; Dioxanes; Insulin Resistance; JNK Mitogen-Activated Protein Kinases; Liver Diseases; Mice; Molecular Mimicry; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Signal Transduction; Thiazoles | 2008 |
[Mechanism of BVT.2733 and pioglitazone in the improvement of insulin resistance].
Topics: Adipose Tissue; Animals; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Pioglitazone; Piperazines; Sulfonamides; Thiazoles; Thiazolidinediones | 2008 |
Design, synthesis, and structure-activity relationship of substrate competitive, selective, and in vivo active triazole and thiadiazole inhibitors of the c-Jun N-terminal kinase.
Topics: Activating Transcription Factor 2; Animals; Binding Sites; Diabetes Mellitus, Type 2; Drug Design; HeLa Cells; Humans; Hypoglycemic Agents; Insulin Resistance; JNK Mitogen-Activated Protein Kinases; Male; Mice; Phosphorylation; Protein Binding; Structure-Activity Relationship; Substrate Specificity; Thiadiazoles; Thiazoles; Triazoles | 2009 |
Modulation of nutrient sensing nuclear hormone receptors promotes weight loss through appetite suppression in mice.
Topics: Animals; Appetite Depressants; Appetite Regulation; Energy Metabolism; Insulin Resistance; Lipid Peroxidation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Obesity; PPAR alpha; PPAR delta; PPAR gamma; Rosiglitazone; Thiazoles; Thiazolidinediones; Weight Loss | 2010 |
Activation of peroxisome proliferator-activated receptor-{delta} by GW501516 prevents fatty acid-induced nuclear factor-{kappa}B activation and insulin resistance in skeletal muscle cells.
Topics: Analysis of Variance; Animals; Blotting, Western; Carnitine O-Palmitoyltransferase; Cell Line; Cell Nucleus; Electrophoretic Mobility Shift Assay; Epoxy Compounds; Fatty Acids; Humans; Insulin Resistance; Interleukin-6; Mice; Muscle, Skeletal; NF-kappa B; PPAR delta; Protein Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfones; Thiazoles; Thiophenes | 2010 |
Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Carnitine; Clozapine; Energy Metabolism; Fatty Acids, Nonesterified; Female; Haloperidol; Insulin Resistance; Lipolysis; Male; Malonyl Coenzyme A; Mice; Olanzapine; Piperazines; Rats; Rats, Sprague-Dawley; Risperidone; Thiazoles; Vitamin B Complex | 2012 |
Oral administration of a PPAR-delta agonist to rodents worsens, not improves, maximal insulin-stimulated glucose transport in skeletal muscle of different fibers.
Topics: Administration, Oral; Animals; Biological Transport; Blood Glucose; CD36 Antigens; Ceramides; Dietary Fats; Diglycerides; Fatty Acid-Binding Proteins; Female; Glucose Transporter Type 4; Glycolysis; GTPase-Activating Proteins; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Muscle Fibers, Skeletal; Oxidation-Reduction; Phosphatidylinositol 3-Kinases; Phosphorylation; PPAR delta; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Thiazoles | 2010 |
PPARδ agonists have opposing effects on insulin resistance in high fat-fed rats and mice due to different metabolic responses in muscle.
Topics: Animals; Biomarkers; Dietary Fats; Glucose; Glucose Tolerance Test; Insulin Resistance; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Organ Specificity; PPAR delta; Rats; Rats, Wistar; RNA, Messenger; Species Specificity; Thiazoles; Triglycerides | 2011 |
In vitro responsiveness of human muscle cell peroxisome proliferator-activated receptor δ reflects donors' insulin sensitivity in vivo.
Topics: Blood Glucose; Body Mass Index; Cells, Cultured; Female; Gene Expression Regulation; Glucose Tolerance Test; Humans; Insulin Resistance; Lipid Metabolism; Male; Muscle Cells; Muscle Fibers, Skeletal; PPAR delta; Regression Analysis; RNA, Messenger; Thiazoles | 2011 |
The peroxisome proliferator-activated receptor (PPAR) β/δ agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells.
Topics: Animals; Cell Nucleus; Gene Expression Regulation; Hep G2 Cells; Hepatocytes; Humans; Insulin Resistance; Interleukin-6; Male; Mice; Mice, Knockout; Phosphorylation; PPAR delta; PPAR-beta; Protein Processing, Post-Translational; Protein Transport; RNA, Messenger; Signal Transduction; STAT3 Transcription Factor; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Thiazoles | 2012 |
BVT.2733, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, attenuates obesity and inflammation in diet-induced obese mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 3T3-L1 Cells; Adipose Tissue; Animals; Body Weight; Chemokine CCL2; Diet; Enzyme Inhibitors; Glucocorticoids; Inflammation; Inflammation Mediators; Insulin Resistance; Macrophages; Male; Mice; Obesity; Piperazines; Sulfonamides; Thiazoles; Tumor Necrosis Factor-alpha | 2012 |
Peroxisome proliferator-activated receptor δ agonist attenuates hepatic steatosis by anti-inflammatory mechanism.
Topics: Animals; Anti-Inflammatory Agents; Blood Glucose; Cytokines; Diabetes Mellitus; Fatty Liver; Glucose Tolerance Test; Hep G2 Cells; Humans; Insulin Resistance; Liver; Male; PPAR delta; Rats; Rats, Long-Evans; Thiazoles; Triglycerides | 2012 |
Understanding insulin-resistance in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; DNA-Binding Proteins; Humans; Insulin Resistance; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
[Prevention of arteriosclerosis with the insulin sensitizer pioglitazone. Early intervention in diabetic patients compensates "cell ignorance"].
Topics: Arteriosclerosis; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
Troglitazone improves blood flow by inhibiting neointimal formation after balloon injury in Otsuka Long-Evans Tokushima fatty rats.
Topics: Animals; Blood Flow Velocity; Blood Glucose; Carotid Arteries; Catheterization; Cell Division; Chromans; Hyperplasia; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Muscle, Smooth, Vascular; Rats; Rats, Long-Evans; Systole; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low-energy diet and an insulin-sensitizing agent.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Blood Pressure; Body Weight; Caloric Restriction; Chromans; Data Interpretation, Statistical; Female; Glucose Tolerance Test; Humans; Hypertension; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Obesity; Thiazoles; Thiazolidinediones; Troglitazone; Uric Acid | 2002 |
PMT13, a pyrimidone analogue of thiazolidinedione improves insulin resistance-associated disorders in animal models of type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypoglycemic Agents; Insulin Resistance; Liver; Mice; Mice, Obese; Pyrimidines; Pyrimidinones; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Troglitazone ameliorates abnormal activity of protein tyrosine phosphatase in adipose tissues of Otsuka Long-Evans Tokushima Fatty rats.
Topics: Adipose Tissue; Animals; Cell Fractionation; Chromans; Diabetes Mellitus; Disease Models, Animal; Hypoglycemic Agents; Insulin Resistance; Male; Obesity; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Protein Tyrosine Phosphatases; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity.
Topics: 3T3 Cells; Adipocytes; Adipose Tissue; Adipose Tissue, Brown; Aged; Animals; Anti-Obesity Agents; Cell Differentiation; Epididymis; HeLa Cells; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mice; Mice, Knockout; Molecular Structure; Organophosphorus Compounds; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver.
Topics: Acyl Coenzyme A; Adiponectin; Animals; Blood Glucose; Fat Emulsions, Intravenous; Fatty Acids, Nonesterified; Glucose; Glucose Clamp Technique; Heparin; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Liver; Male; Muscle, Skeletal; Phosphorylation; Pioglitazone; Protein Serine-Threonine Kinases; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones | 2002 |
Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats.
Topics: Animals; Body Composition; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Eating; Fatty Acids, Nonesterified; Glucose Clamp Technique; Glycated Hemoglobin; Glycogen; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Liver; Male; Oxazines; Phenylpropionates; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Are thiazolidinediones first-line agents?
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Sensitivity and Specificity; Thiazoles | 2002 |
Adipose tissue sensitization to insulin induced by troglitazone and MEDICA 16 in obese Zucker rats in vivo.
Topics: Adipose Tissue; Animals; Chromans; Esterification; Fasting; Fatty Acids, Nonesterified; Glycerol; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Lipolysis; Male; Obesity; Palmitic Acids; Rats; Rats, Zucker; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
Intramyocellular lipid and insulin resistance: a longitudinal in vivo 1H-spectroscopic study in Zucker diabetic fatty rats.
Topics: Adipose Tissue; Animals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Insulin Resistance; Lipid Metabolism; Liver; Longitudinal Studies; Magnetic Resonance Spectroscopy; Male; Muscle, Skeletal; Obesity; Organ Size; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Development of insulin resistance and reversal by thiazolidinediones in C2C12 skeletal muscle cells.
Topics: Animals; Biological Transport; Cell Differentiation; Cells, Cultured; Culture Media, Serum-Free; Deoxyglucose; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Mice; Muscle, Skeletal; Myoblasts; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Pioglitazone; Receptor, Insulin; Rosiglitazone; Thiazoles; Thiazolidinediones; Tyrosine | 2003 |
Rosiglitazone improves insulin resistance, lipid profile and promotes adiposity in a genetic model of metabolic syndrome X.
Topics: Adipose Tissue; Animals; Disease Models, Animal; Glucose; Glucose Tolerance Test; Glycogen; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Metabolic Syndrome; Rats; Rats, Inbred Strains; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Is programming of glucocorticoid receptor expression by prenatal dexamethasone in the rat secondary to metabolic derangement in adulthood?
Topics: Animals; Appetite; Body Weight; Corticosterone; Dexamethasone; Female; Gene Expression; Glucocorticoids; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metformin; Organ Size; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar; Receptors, Glucocorticoid; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency.
Topics: Aging; Animals; Aromatase; Bezafibrate; Blood Glucose; Cholesterol; Estradiol; Glucose Tolerance Test; Insulin; Insulin Resistance; Male; Mice; Mice, Knockout; Models, Animal; Obesity; Pioglitazone; Testosterone; Thiazoles; Thiazolidinediones; Triglycerides | 2003 |
PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly.
Topics: Animals; Dietary Fats; Fatty Liver; Glucose; Glucose Clamp Technique; Insulin; Insulin Resistance; Lipid Metabolism; Liver; Male; Muscle, Skeletal; Oxazines; Phenylpropionates; Pyrimidines; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Effect of heterozygous PPARgamma deficiency and TZD treatment on insulin resistance associated with age and high-fat feeding.
Topics: Aging; Animals; Chromans; Dietary Fats; Heterozygote; Insulin Resistance; Metabolism, Inborn Errors; Mice; Mice, Inbred C57BL; Mice, Knockout; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2003 |
Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes.
Topics: Animals; Blood Glucose; Fatty Acids, Nonesterified; Fatty Liver; Hyperglycemia; Insulin Resistance; Leptin; Lipoprotein Lipase; Lipoproteins, VLDL; Liver; Mice; Mice, Inbred C57BL; Mice, Obese; Receptors, Cytoplasmic and Nuclear; Receptors, LDL; Receptors, Leptin; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2003 |
Phenylacetic acid derivatives as hPPAR agonists.
Topics: Animals; Blood Glucose; Dose-Response Relationship, Drug; Drug Design; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Phenylacetates; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2003 |
Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma.
Topics: Abdomen; Adipose Tissue; Adult; Body Composition; Carrier Proteins; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids; Fatty Acids, Nonesterified; Fatty Liver; Female; Gene Expression; Humans; Hyperlipidemias; Insulin Resistance; Kinetics; Liver; Magnetic Resonance Imaging; Male; Metabolic Syndrome; Middle Aged; Mutation; Neoplasm Proteins; Phenotype; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides; Tumor Suppressor Proteins | 2003 |
[Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes].
Topics: 1-Deoxynojirimycin; Acarbose; Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Glucosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin Resistance; Insulin Secretion; Metformin; Obesity; Pioglitazone; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Time Factors | 2003 |
[When HbA1c cannot be pushed down under 7. Don't hesitate to use a 2d antidiabetic agent].
Topics: Diabetes Mellitus; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects.
Topics: Adult; CD36 Antigens; Cells, Cultured; Chromans; Diabetes Mellitus, Type 2; Fatty Acids; Fatty Acids, Nonesterified; Female; Gene Expression; Humans; Insulin Resistance; Male; Membrane Glycoproteins; Middle Aged; Muscle, Skeletal; Organic Anion Transporters; Oxidation-Reduction; Palmitic Acid; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
Marked improvement of glycaemic control with pioglitazone in a Type 2 diabetic patient associated with Charcot-Marie-Tooth disease.
Topics: Body Weight; Charcot-Marie-Tooth Disease; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2003 |
Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice.
Topics: Adipocytes; Adipose Tissue; Animals; Blood Glucose; Body Weight; Female; Glucose Clamp Technique; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Mice; Mice, Mutant Strains; Muscle, Skeletal; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass.
Topics: Adipose Tissue; Animals; Blotting, Southern; Blotting, Western; Female; Hypoglycemia; Insulin Resistance; Lipid Metabolism; Liver; Liver Diseases; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Receptors, Cytoplasmic and Nuclear; Recombination, Genetic; RNA; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Triglycerides | 2003 |
[Preventing infarct in the diabetic patient. Lowering blood glucose and HbA1c are not enough].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Myocardial Infarction; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Rosiglitazone improves muscle insulin sensitivity, irrespective of increased triglyceride content, in ob/ob mice.
Topics: Animals; Blood Glucose; Body Weight; Cholesterol; Diet; Fatty Acids, Nonesterified; Glucose Clamp Technique; Glucose Tolerance Test; Heart; Hypoglycemic Agents; Insulin Resistance; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Myocardium; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 2003 |
Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones.
Topics: Adipose Tissue; Alleles; Animals; Deoxyglucose; Fatty Acids; Genotype; Glucose; Glucose Tolerance Test; Insulin; Insulin Resistance; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Knockout; Mice, Transgenic; Models, Genetic; Muscle, Skeletal; Muscles; Oligonucleotide Array Sequence Analysis; Receptors, Cytoplasmic and Nuclear; Recombination, Genetic; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Triglycerides | 2003 |
A PPAR agonist improves TNF-alpha-induced insulin resistance of adipose tissue in mice.
Topics: Adipose Tissue; Animals; Blood Glucose; Cells, Cultured; Glucose; Glucose Tolerance Test; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Lipoprotein Lipase; Male; Mice; Mice, Inbred ICR; Mice, Nude; Muscle, Skeletal; Phosphoproteins; Phosphorylation; Pioglitazone; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2003 |
Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes.
Topics: Animals; Blood Glucose; Carotid Arteries; Carotid Artery Injuries; Cells, Cultured; Diabetes Mellitus, Type 2; Diet; Disease Models, Animal; Female; Homozygote; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Islets of Langerhans; Lipids; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Smooth, Vascular; Rosiglitazone; Thiazoles; Thiazolidinediones; Tunica Intima | 2003 |
Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome.
Topics: Animals; Dimethyl Sulfoxide; Enzymes; Fatty Acids, Nonesterified; Insulin Resistance; Lipid Metabolism; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mice, Obese; Muscle, Skeletal; Oxidation-Reduction; Rats; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors | 2003 |
[Ovarian insulin resistance and insulin sensitizer effect on polycystic ovary syndrome].
Topics: Adult; Cells, Cultured; Female; Glycogen; Humans; Insulin; Insulin Resistance; Insulin-Like Growth Factor I; Ovary; Polycystic Ovary Syndrome; Signal Transduction; Thiazoles | 2004 |
A computational model to define the molecular causes of type 2 diabetes mellitus.
Topics: Algorithms; Blood Glucose; Computer Simulation; Diabetes Mellitus, Type 2; Gene Expression Regulation; Genome; Humans; Insulin Resistance; Mexican Americans; Models, Statistical; Muscle, Skeletal; Oxidative Phosphorylation; RNA; Scandinavian and Nordic Countries; Thiazoles | 2005 |
A novel thiazolidinedione MCC-555 down-regulates tumor necrosis factor-alpha-induced expression of vascular cell adhesion molecule-1 in vascular endothelial cells.
Topics: Aorta; Cell Adhesion; Down-Regulation; Endothelium, Vascular; Gene Expression; Humans; Hypoglycemic Agents; Insulin Resistance; NF-kappa B; PPAR alpha; PPAR gamma; Promoter Regions, Genetic; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha; U937 Cells; Vascular Cell Adhesion Molecule-1 | 2005 |
Does antipsychotic polypharmacy increase the risk for metabolic syndrome?
Topics: Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Mass Index; Cholesterol, HDL; Clozapine; Cross-Sectional Studies; Dibenzothiazepines; Drug Therapy, Combination; Female; Humans; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Piperazines; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Thiazoles; Triglycerides | 2007 |
Inhibition of 11betaHSD1 with the S-phenylethylaminothiazolone BVT116429 increases adiponectin concentrations and improves glucose homeostasis in diabetic KKAy mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adiponectin; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Enzyme Inhibitors; Homeostasis; Insulin Resistance; Male; Mice; Mice, Mutant Strains; Phenethylamines; Thiazoles | 2008 |
Ciglitazone reverses cAMP-induced post-insulin receptor resistance in rat adipocytes in vitro.
Topics: 3-O-Methylglucose; Adipose Tissue; Animals; Biological Transport; Cyclic AMP; Insulin; Insulin Resistance; Isoproterenol; Male; Methylglucosides; Rats; Receptor, Insulin; Thiazoles; Thiazolidinediones | 1984 |
Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent.
Topics: Animals; Blood Glucose; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Experimental; Dogs; Fatty Acids, Nonesterified; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mice; Mice, Obese; Obesity; Phospholipids; Rats; Rats, Inbred Strains; Thiazoles; Thiazolidinediones; Triglycerides | 1983 |
Ciglitazone, a new hypoglycemic agent. II. Effect on glucose and lipid metabolisms and insulin binding in the adipose tissue of C57BL/6J-ob/ob and -+/? mice.
Topics: Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Fatty Acids, Nonesterified; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Thiazoles; Thiazolidinediones | 1983 |
Metabolic effects of troglitazone on fat-induced insulin resistance in the rat.
Topics: Animals; Blood Pressure; Body Weight; Chromans; Dietary Fats; Eating; Glucose; Glucose Clamp Technique; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Liver; Male; Rats; Rats, Sprague-Dawley; Thiazoles; Thiazolidinediones; Troglitazone | 1995 |
Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cell Line; Chromans; Fibroblasts; Glucose; Humans; Hypoglycemic Agents; Immunoblotting; Immunosorbent Techniques; Insulin Resistance; Isoquinolines; Kinetics; Phosphorylation; Phosphotyrosine; Piperazines; Rats; Receptor, Insulin; Thiazoles; Thiazolidinediones; Troglitazone; Tyrosine | 1994 |
Thiazolidine derivatives ameliorate high glucose-induced insulin resistance via the normalization of protein-tyrosine phosphatase activities.
Topics: Aminoisobutyric Acids; Animals; Biological Transport; Blotting, Western; Cell Line; Cytosol; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Kinetics; Macromolecular Substances; Phosphotyrosine; Pioglitazone; Protein Tyrosine Phosphatases; Raffinose; Rats; Receptor, Insulin; Recombinant Proteins; Swine; Thiazoles; Thiazolidinediones; Transfection; Tyrosine | 1995 |
New directions in treating insulin resistance.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Thiazoles; Thiazolidinediones; Troglitazone | 1995 |
Polyunsaturated fatty acid-mediated suppression of insulin-dependent gene expression of lipogenic enzymes in rat liver.
Topics: Acetyl-CoA Carboxylase; Animals; ATP Citrate (pro-S)-Lyase; Corn Oil; Diabetes Mellitus, Experimental; Fatty Acid Synthases; Fatty Acids, Unsaturated; Gene Expression Regulation, Enzymologic; Glucosephosphate Dehydrogenase; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Malate Dehydrogenase; Male; Phosphorylation; Pioglitazone; Rats; Rats, Wistar; Receptor, Insulin; RNA, Messenger; Thiazoles; Thiazolidinediones | 1995 |
Insulin secretory defect in Zucker fa/fa rats is improved by ameliorating insulin resistance.
Topics: Aging; Amino Acids; Animals; Blood Glucose; Fatty Acids, Nonesterified; Female; Glucose; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Pioglitazone; Rats; Rats, Zucker; Reference Values; Thiazoles; Thiazolidinediones; Tolbutamide | 1995 |
Pioglitazone attenuates diet-induced hypertension in rats.
Topics: Animals; Blood Glucose; Blood Pressure; Diet; Dietary Carbohydrates; Dietary Fats; Hypertension; Insulin; Insulin Resistance; Male; Pioglitazone; Rats; Rats, Sprague-Dawley; Thiazoles; Thiazolidinediones | 1995 |
Treatment with the thiazolidinedione (BRL 49653) decreases insulin resistance in obese Zucker hindlimb.
Topics: Adipose Tissue; Animals; Hindlimb; Insulin Resistance; Male; Muscle, Skeletal; Perfusion; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones | 1995 |
Insulin sensitization in diabetic rat liver by an antihyperglycemic agent.
Topics: Animals; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Gene Expression; Glucokinase; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Phosphoenolpyruvate Carboxykinase (GTP); Pioglitazone; Rats; Rats, Sprague-Dawley; RNA, Messenger; Thiazoles; Thiazolidinediones | 1995 |
Thiazolidinediones (AD-4833 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats.
Topics: Animals; Chromans; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Glucose; Glucose Clamp Technique; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Pioglitazone; Rats; Rats, Wistar; Streptozocin; Thiazoles; Thiazolidinediones; Troglitazone | 1993 |
A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat.
Topics: 3-Hydroxybutyric Acid; Adipose Tissue; Adipose Tissue, Brown; Animals; Biological Availability; Blood Glucose; Dietary Carbohydrates; Dietary Fats; Fatty Acids, Nonesterified; Glucose; Glucose Clamp Technique; Glycerol; Heart; Hydroxybutyrates; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Liver; Liver Glycogen; Male; Muscles; Myocardium; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 1994 |
Insulin resistance and the prevention of diabetes mellitus.
Topics: Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Obesity; Thiazoles; Thiazolidinediones; Troglitazone | 1994 |
Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat.
Topics: Animals; Blood Glucose; Blood Pressure; Chromans; Fructose; Glucose Clamp Technique; Hypoglycemic Agents; Insulin; Insulin Resistance; Kinetics; Male; Rats; Rats, Sprague-Dawley; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 1994 |
Increased insulin responsiveness after CS-045 treatment in diabetes associated with Werner's syndrome.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Thiazoles; Thiazolidinediones; Troglitazone; Werner Syndrome | 1994 |
Lipid abnormalities in tissues of the KKAy mouse: effects of pioglitazone on malonyl-CoA and diacylglycerol.
Topics: Animals; Blood; Diglycerides; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Liver; Male; Malonyl Coenzyme A; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Muscles; Obesity; Pioglitazone; Thiazoles; Thiazolidinediones | 1994 |
Evidence against a role of insulin in hypertension in spontaneously hypertensive rats. CS-045 does not lower blood pressure despite improvement of insulin resistance.
Topics: Animals; Blood Glucose; Blood Pressure; Chromans; Glucose; Homeostasis; Hypertension; Insulin; Insulin Resistance; Male; Rats; Rats, Inbred SHR; Rats, Wistar; Thiazoles; Thiazolidinediones; Troglitazone | 1994 |
Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance.
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Gene Expression; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Muscles; Obesity; Pioglitazone; Receptors, Tumor Necrosis Factor; RNA, Messenger; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha | 1994 |
Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Eating; Fasting; Feeding Behavior; Female; Glucose Tolerance Test; Heart Rate; Hypoglycemic Agents; Insulin; Insulin Resistance; Macaca mulatta; Male; Obesity; Pioglitazone; Thiazoles; Thiazolidinediones; Tolbutamide; Triglycerides | 1994 |
Pioglitazone inhibits the diabetogenic action of growth hormone, but not its ability to promote growth.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Feeding Behavior; Female; Growth Hormone; Humans; Hypoglycemic Agents; Hypophysectomy; Insulin Resistance; Mice; Mice, Obese; Pioglitazone; Thiazoles; Thiazolidinediones | 1994 |
Effect of pioglitazone on insulin receptors of skeletal muscles from high-fat-fed rats.
Topics: Animals; Diabetes Mellitus, Type 2; Dietary Fats; Electrophoresis, Polyacrylamide Gel; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Muscles; Phosphorylation; Pioglitazone; Precipitin Tests; Protein-Tyrosine Kinases; Rats; Rats, Sprague-Dawley; Receptor, Insulin; Thiazoles; Thiazolidinediones | 1993 |
Hepatic insulin resistance in KKA(y) mice and its amelioration by pioglitazone do not involve alterations in phospholipase C activity.
Topics: Animals; Cell Membrane; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Phosphoinositide Phospholipase C; Phosphoric Diester Hydrolases; Pioglitazone; Thiazoles; Thiazolidinediones | 1993 |
Effects of thiazolidinediones on glucocorticoid-induced insulin resistance and GLUT4 glucose transporter expression in rat skeletal muscle.
Topics: Animals; Benzopyrans; Blood Glucose; Deoxyglucose; Dexamethasone; Glucocorticoids; Glucose Transporter Type 4; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Isomerism; Male; Monosaccharide Transport Proteins; Muscle Proteins; Muscles; Pioglitazone; Rats; Rats, Sprague-Dawley; Thiazoles; Thiazolidinediones; Tritium | 1993 |
Antihypertensive effects of CS-045 treatment in obese Zucker rats.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Chromans; Diuresis; Female; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Obesity; Rats; Rats, Zucker; Thiazoles; Thiazolidinediones; Troglitazone | 1993 |
A study of effect of CS-045, a new antidiabetic drug, on hypertension in spontaneously hypertensive rat.
Topics: Animals; Blood Glucose; Blood Pressure; Chromans; Hypertension; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Thiazoles; Thiazolidinediones; Troglitazone | 1995 |
Effect of troglitazone, a new oral antidiabetic agent, on fructose-induced insulin resistance.
Topics: Aging; Animals; Blood Glucose; Body Weight; Chromans; Fructose; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Rats; Rats, Sprague-Dawley; Thiazoles; Thiazolidinediones; Troglitazone | 1995 |
Malonyl coenzyme A and adiposity in the Dahl salt-sensitive rat: effects of pioglitazone.
Topics: Adipose Tissue; Animals; Blood Glucose; Blood Pressure; Dietary Carbohydrates; Dietary Fats; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Malonyl Coenzyme A; Muscle, Skeletal; Pioglitazone; Rats; Rats, Sprague-Dawley; Sodium Chloride; Thiazoles; Thiazolidinediones; Triglycerides | 1996 |
An antidiabetic thiazolidinedione potentiates insulin stimulation of glycogen synthase in rat adipose tissues.
Topics: Adipose Tissue; Animals; Catecholamines; Drug Synergism; Glucose; Glycogen Synthase; Hypoglycemic Agents; Insulin; Insulin Resistance; Kinetics; Male; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones | 1996 |
Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice.
Topics: Animals; Blood Glucose; COS Cells; Cricetinae; Diabetes Mellitus; Hyperglycemia; Hypertriglyceridemia; Insulin Resistance; Male; Mice; Molecular Conformation; Peptide Hydrolases; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors; Triglycerides | 1996 |
Euglycaemic and biological activities of novel thiazolidine-2,4-dione derivatives.
Topics: Animals; Blood Glucose; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Rats; Rats, Zucker; Thiazoles | 1995 |
A comparison of the hypotensive and hypoglycaemic actions of an angiotensin converting enzyme inhibitor, an AT1a antagonist and troglitazone.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Blood Pressure; Captopril; Chromans; Diet; Fructose; Hypoglycemic Agents; Insulin Resistance; Male; Monosaccharide Transport Proteins; Rats; Rats, Wistar; Tetrazoles; Thiazoles; Thiazolidinediones; Troglitazone | 1996 |
Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent pioglitazone.
Topics: Animals; Dogs; Half-Life; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Mice; Pioglitazone; Rats; Thiazoles; Thiazolidinediones | 1996 |
"Glitazones", a prospect for non-insulin-dependent diabetes.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
The effect of pioglitazone on hepatic glucose uptake measured with indirect and direct methods in alloxan-induced diabetic dogs.
Topics: Animals; Biological Transport; Blood Pressure; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dogs; Glucagon; Glucose; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Pioglitazone; Thiazoles; Thiazolidinediones | 1997 |
Metabolic effects of troglitazone in the Goto-Kakizaki rat, a non-obese and normolipidemic rodent model of non-insulin-dependent diabetes mellitus.
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Glucose; Glucose Clamp Technique; Glucose Tolerance Test; Hypoglycemic Agents; Injections, Intravenous; Insulin Resistance; Male; Rats; Rats, Inbred Strains; Rats, Wistar; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Quantification of the effects of troglitazone on insulin sensitivity and beta-cell function in Watanabe heritable hyperlipidemic rabbits: a minimal model analysis.
Topics: Animals; Blood Glucose; Chromans; Disease Models, Animal; Fasting; Female; Glucose Tolerance Test; Hypercholesterolemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Models, Biological; Rabbits; Random Allocation; Thiazoles; Thiazolidinediones; Time Factors; Troglitazone | 1997 |
New diabetes drug targets insulin resistance.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists.
Topics: Animals; Bexarotene; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulin Resistance; Ligands; Mice; Mice, Inbred C57BL; Mice, Obese; Nicotinic Acids; Obesity; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Rosiglitazone; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors; Transfection | 1997 |
Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.
Topics: Adult; Androgens; Chromans; Female; Fibrinolysis; Glucose; Glucose Tolerance Test; Gonadotropins; Humans; Insulin; Insulin Resistance; Leuprolide; Plasminogen Activator Inhibitor 1; Polycystic Ovary Syndrome; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Reduction of insulin resistance attenuates the development of hypertension in sucrose-fed SHR.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Captopril; Catecholamines; Dietary Sucrose; Glucose Tolerance Test; Hexamethonium; Hypertension; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Pioglitazone; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Renin; Thiazoles; Thiazolidinediones | 1997 |
Troglitazone ameliorates insulin resistance in patients with Werner's syndrome.
Topics: Adult; Blood Glucose; Chromans; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Kinetics; Male; Middle Aged; Thiazoles; Thiazolidinediones; Troglitazone; Werner Syndrome | 1997 |
KB-R7785, a novel matrix metalloproteinase inhibitor, exerts its antidiabetic effect by inhibiting tumor necrosis factor-alpha production.
Topics: Animals; Blood Glucose; Body Weight; Glycine; Hydroxamic Acids; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metalloendopeptidases; Mice; Mice, Inbred BALB C; Pioglitazone; Protease Inhibitors; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha | 1997 |
Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat.
Topics: Adipocytes; Animals; Body Weight; Cell Differentiation; Fatty Acid Synthases; Female; Gene Expression Regulation; Gene Expression Regulation, Enzymologic; Glucose; Glucose Transporter Type 4; Insulin Resistance; Leptin; Lipid Metabolism; Lipid Mobilization; Monosaccharide Transport Proteins; Muscle Proteins; Obesity; Phosphoenolpyruvate Carboxykinase (GTP); Pioglitazone; Proteins; Rats; Rats, Mutant Strains; Thiazoles; Thiazolidinediones | 1997 |
Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor-alpha in liver cells.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Liver Neoplasms, Experimental; Metformin; Pioglitazone; Rats; Thiazoles; Thiazolidinediones; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1997 |
Effect of an insulin sensitizer, pioglitazone, on hypertension in fructose-drinking rats.
Topics: Animals; Blood Glucose; Blood Pressure; Disease Models, Animal; Drinking; Fructose; Hypertension; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Pioglitazone; Rats; Rats, Inbred WKY; Thiazoles; Thiazolidinediones; Time Factors; Triglycerides | 1997 |
Increasing insulin sensitivity lowers blood pressure in the fructose-fed rat.
Topics: Acetylcholine; Adipocytes; Animals; Blood Pressure; Fructose; Glucose; Insulin; Insulin Resistance; Male; Norepinephrine; Pioglitazone; Rats; Rats, Sprague-Dawley; Thiazoles; Thiazolidinediones; Vasoconstrictor Agents; Vasodilation | 1997 |
Troglitazone lowers blood pressure and enhances insulin sensitivity in Watanabe heritable hyperlipidemic rabbits.
Topics: Animals; Blood Pressure; Chromans; Female; Heart Rate; Hyperlipidemias; Insulin; Insulin Resistance; Rabbits; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Insulin resistance.
Topics: Diabetes Mellitus, Type 2; Hexosamines; Humans; Insulin Resistance; Thiazoles; Tumor Necrosis Factor-alpha | 1997 |
TNF-alpha-induced insulin resistance in vivo and its prevention by troglitazone.
Topics: Adenosine Triphosphate; Animals; Blood Glucose; Chromans; Fatty Acids, Nonesterified; Glucose Clamp Technique; Hyperinsulinism; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Insulin Resistance; Male; Muscle, Skeletal; Rats; Rats, Sprague-Dawley; Receptor, Insulin; Thiazoles; Thiazolidinediones; Troglitazone; Tumor Necrosis Factor-alpha | 1997 |
Pioglitazone-reduced insulin resistance in patient with Werner syndrome.
Topics: Blood Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones; Werner Syndrome | 1997 |
Troglitazone action is independent of adipose tissue.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Cholesterol; Chromans; Diabetes Mellitus, Type 2; Eating; Fatty Acids; Glycogen; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Leptin; Lipoproteins, LDL; Lipoproteins, VLDL; Mice; Mice, Transgenic; Organ Size; Proteins; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides; Troglitazone | 1997 |
Thiazolidinediones stimulate uncoupling protein-2 expression in cell lines representing white and brown adipose tissues and skeletal muscle.
Topics: Adipose Tissue; Animals; Cell Line; Chromans; Gene Expression Regulation; Hypoglycemic Agents; Insulin Resistance; Ion Channels; Membrane Transport Proteins; Mice; Mitochondrial Proteins; Muscle, Skeletal; Proteins; Rats; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Uncoupling Protein 2 | 1998 |
Thiazolidinediones and their effects on glucose transporters.
Topics: Animals; Chromans; Gene Expression Regulation; Glucose; Hypoglycemic Agents; Insulin Resistance; Monosaccharide Transport Proteins; Rats; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 1997 |
Insulin sensitizer YM268 ameliorates insulin resistance by normalizing the decreased content of GLUT4 in adipose tissue of obese Zucker rats.
Topics: Adipose Tissue; Animals; Blood Glucose; Glucose Transporter Type 4; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Monosaccharide Transport Proteins; Muscle Proteins; Rats; Rats, Zucker; Thiazoles; Thiazolidines | 1997 |
Effects of troglitazone on dexamethasone-induced insulin resistance in rats.
Topics: Animals; Blood Glucose; Chromans; Dexamethasone; Glucocorticoids; Glucose; Glucose Clamp Technique; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.
Topics: Adipocytes; Adipose Tissue; Animals; Apoptosis; Blood Glucose; Blotting, Northern; Body Weight; Chromans; DNA; DNA, Complementary; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Leptin; Male; Mesentery; Polymerase Chain Reaction; Proteins; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Retroperitoneal Space; RNA; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides; Troglitazone; Tumor Necrosis Factor-alpha | 1998 |
Troglitazone prevents hyperglycemia-induced but not glucosamine-induced insulin resistance.
Topics: Administration, Oral; Animals; Blood Glucose; Chromans; Cohort Studies; Glucosamine; Glucose Clamp Technique; Hormone Antagonists; Hypoglycemic Agents; Infusion Pumps; Insulin Resistance; Male; Rats; Rats, Sprague-Dawley; Somatostatin; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Pioglitazone time-dependently reduces tumour necrosis factor-alpha level in muscle and improves metabolic abnormalities in Wistar fatty rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Immunoenzyme Techniques; Insulin; Insulin Resistance; Male; Muscle, Skeletal; Obesity; Pioglitazone; Rats; Rats, Mutant Strains; Rats, Wistar; Sphingomyelin Phosphodiesterase; Thiazoles; Thiazolidinediones; Time Factors; Triglycerides; Tumor Necrosis Factor-alpha | 1998 |
Troglitazone suppresses intimal formation following balloon injury in insulin-resistant Zucker fatty rats.
Topics: Animals; Catheterization; Cell Division; Cells, Cultured; Chromans; DNA; Endothelium, Vascular; Insulin Resistance; Male; Muscle, Smooth, Vascular; Rats; Rats, Zucker; Thiazoles; Thiazolidinediones; Troglitazone; Tunica Intima | 1998 |
Troglitazone enhances glucose uptake and inhibits mitogen-activated protein kinase in human aortic smooth muscle cells.
Topics: Aorta; Arteriosclerosis; Calcium-Calmodulin-Dependent Protein Kinases; Cell Division; Cells, Cultured; Chromans; DNA Replication; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Muscle, Smooth, Vascular; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
BRL 49653 blocks the lipolytic actions of tumor necrosis factor-alpha: a potential new insulin-sensitizing mechanism for thiazolidinediones.
Topics: 3T3 Cells; Adipocytes; Animals; Carrier Proteins; Fatty Acids, Nonesterified; Glycerol; Hypoglycemic Agents; Insulin Resistance; Lipolysis; Mice; Perilipin-1; Phosphoproteins; Prostaglandin D2; Rosiglitazone; Sterol Esterase; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha | 1998 |
Specific activation of the nuclear receptors PPARgamma and RORA by the antidiabetic thiazolidinedione BRL 49653 and the antiarthritic thiazolidinedione derivative CGP 52608.
Topics: 3T3 Cells; Animals; Arthritis, Experimental; Cell Nucleus; Dexamethasone; Hypoglycemic Agents; Insulin Resistance; Leptin; Male; Mice; Proteins; Rats; Rats, Inbred Lew; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiosemicarbazones; Transcription Factors; Triglycerides | 1998 |
Insulin-sensitising agents in polycystic-ovary syndrome.
Topics: Chromans; Controlled Clinical Trials as Topic; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Syndrome; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 1998 |
Effects of troglitazone on hepatic and peripheral insulin resistance induced by growth hormone excess in rats.
Topics: Administration, Oral; Animals; Chromans; Glucose; Glucose Clamp Technique; Human Growth Hormone; Hypoglycemic Agents; Injections, Subcutaneous; Insulin Resistance; Liver; Male; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Troglitazone and small low-density lipoprotein in type 2 diabetes.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Lipoproteins, LDL; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Ways of changing sensitivity to insulin.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Thiazolidinediones inhibit lipoprotein lipase activity in adipocytes.
Topics: Adipocytes; Animals; Biological Transport; Cell Differentiation; CHO Cells; Chromans; Cricetinae; Enzyme Inhibitors; Gene Expression Regulation; Glucose; Insulin; Insulin Resistance; Lipids; Lipoprotein Lipase; Mice; Protein Biosynthesis; Rats; RNA, Messenger; Rosiglitazone; Stem Cells; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 1998 |
Troglitazone reduces free fatty acid-induced insulin resistance in perfused rat hindquarter.
Topics: Animals; Chromans; Fatty Acids, Nonesterified; Hindlimb; Hypoglycemic Agents; Insulin; Insulin Resistance; Palmitic Acid; Perfusion; Rats; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 1998 |
A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties.
Topics: 3T3 Cells; Adipocytes; Animals; Cell Differentiation; Gene Expression Regulation; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Thiazoles; Thiazolidinediones; Transcription Factors | 1998 |
Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action.
Topics: Animals; Deoxyglucose; Humans; Hypoglycemic Agents; In Vitro Techniques; Insulin; Insulin Resistance; Male; Mice; Muscle, Skeletal; Myocardium; Obesity; Rats; Rats, Sprague-Dawley; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 1998 |
Thiazolidinediones and insulin resistance: peroxisome proliferatoractivated receptor gamma activation stimulates expression of the CAP gene.
Topics: Adipocytes; Animals; Gene Expression Regulation; Insulin Resistance; Mice; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-cbl; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors; Ubiquitin-Protein Ligases | 1998 |
Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555.
Topics: Animals; Basal Metabolism; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Fatty Acids; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver Glycogen; Male; Obesity; Rats; Rats, Zucker; Thiazoles; Thiazolidinediones; Treatment Outcome; Triglycerides | 1998 |
Troglitazone ameliorates insulin resistance in a diabetic patient with Prader-Willi syndrome.
Topics: Adolescent; Blood Glucose; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 1; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Obesity; Prader-Willi Syndrome; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits.
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Blood Glucose; Cholesterol, LDL; Chromans; Coronary Vessels; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Glucose Tolerance Test; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperinsulinism; Hyperlipoproteinemia Type II; Hypoglycemic Agents; Insulin Resistance; Male; Pravastatin; Rabbits; Thiazoles; Thiazolidinediones; Troglitazone; Xanthomatosis | 1999 |
Complementary measures for promoting insulin sensitivity in skeletal muscle.
Topics: Adipocytes; Animals; Chromans; Chromium; Fatty Acids, Nonesterified; Fish Oils; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Liver; Muscle, Skeletal; Protein Kinase C; Receptor, Insulin; Thiazoles; Thiazolidinediones; Troglitazone; Vanadium; Vitamin E | 1998 |
Mechanism of hexosamine-induced insulin resistance in transgenic mice overexpressing glutamine:fructose-6-phosphate amidotransferase: decreased glucose transporter GLUT4 translocation and reversal by treatment with thiazolidinedione.
Topics: Animals; Chromans; Gene Expression Regulation, Enzymologic; Glucose; Glucose Clamp Technique; Glucose Transporter Type 4; Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing); Hexosamines; Hypoglycemic Agents; Insulin Resistance; Liver; Mice; Mice, Transgenic; Monosaccharide Transport Proteins; Muscle Proteins; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 1999 |
Troglitazone not only reduced insulin resistance but also improved myotonia in a patient with myotonic dystrophy.
Topics: Adult; Chromans; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Myotonic Dystrophy; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 1999 |
Troglitazone and metformin, but not glibenclamide, decrease blood pressure in Otsuka Long Evans Tokushima Fatty rats.
Topics: Animals; Blood Glucose; Blood Pressure; Catecholamines; Chromans; Diabetes Mellitus, Type 2; Glucose Transporter Type 4; Glyburide; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Metformin; Monosaccharide Transport Proteins; Muscle Proteins; Rats; Rats, Inbred OLETF; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Pregnancy after treatment with the insulin-sensitizing agent troglitazone in an obese woman with the hyperandrogenic, insulin-resistant acanthosis nigricans syndrome.
Topics: Acanthosis Nigricans; Adult; Blood Glucose; Chromans; Female; Gonadal Steroid Hormones; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Obesity; Pregnancy; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Effects of troglitazone on substrate storage and utilization in insulin-resistant rats.
Topics: Animals; Body Weight; Chromans; Eating; Glucose; Glycogen; In Vitro Techniques; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Lipoprotein Lipase; Muscle, Skeletal; Palmitates; Pyruvate Dehydrogenase Complex; Rats; Rats, Zucker; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 1999 |
Switching insulin-sensitizing agents in patients with type 2 diabetes who require insulin.
Topics: Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Tumor necrosis factor alpha-induced pancreatic beta-cell insulin resistance is mediated by nitric oxide and prevented by 15-deoxy-Delta12,14-prostaglandin J2 and aminoguanidine. A role for peroxisome proliferator-activated receptor gamma activation and in
Topics: Animals; Chromans; Guanidines; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Male; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Phosphorylation; Prostaglandin D2; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Ribosomal Protein S6 Kinases; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Necrosis Factor-alpha | 1999 |
The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats.
Topics: Acetylcholine; Animals; Blood Pressure; Endothelium, Vascular; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Obesity; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Vascular Resistance; Vasodilator Agents | 1999 |
Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus.
Topics: Angina Pectoris, Variant; Chromans; Diabetic Angiopathies; Endothelium, Vascular; Humans; Insulin Resistance; Thiazoles; Thiazolidinediones; Time Factors; Troglitazone; Vasodilator Agents | 1999 |
Hypertension and insulin resistance: role of peroxisome proliferator-activated receptor gamma.
Topics: Adipose Tissue; Animals; Epididymis; Gene Expression; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Male; Muscle, Smooth, Vascular; Organ Specificity; Oxidative Stress; Rats; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazoles; Transcription Factors | 1999 |
Triglyceride-lowering effect of a novel insulin-sensitizing agent, JTT-501.
Topics: Animals; Blood Glucose; Body Weight; Dietary Fats; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Isoxazoles; Male; Pioglitazone; Rats; Rats, Sprague-Dawley; Thiazoles; Thiazolidinediones; Triglycerides | 1999 |
Dehydroepiandrosterone suppresses the elevated hepatic glucose-6-phosphatase and fructose-1,6-bisphosphatase activities in C57BL/Ksj-db/db mice: comparison with troglitazone.
Topics: Androstenedione; Animals; Blood Glucose; Body Composition; Chromans; Dehydroepiandrosterone; Diabetes Mellitus; Eating; Fructose-Bisphosphatase; Glucose-6-Phosphatase; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Improvement in insulin resistance and the restoration of reduced phosphodiesterase 3B gene expression by pioglitazone in adipose tissue of obese diabetic KKAy mice.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adipose Tissue; Animals; Blood Glucose; Cyclic Nucleotide Phosphodiesterases, Type 3; Diabetes Mellitus; Diabetes Mellitus, Experimental; Fatty Acids, Nonesterified; Gene Expression Regulation, Enzymologic; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Obesity; Pioglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 1999 |
PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance.
Topics: Adipocytes; Animals; Blood Glucose; Body Weight; Cell Differentiation; Cell Size; Diet; Eating; Energy Metabolism; Fats; Fetal Viability; Hypoglycemic Agents; Insulin Resistance; Leptin; Mice; Mice, Knockout; Myocardium; Pioglitazone; Placenta; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 1999 |
[Type II diabetes mellitus. Rosiglitazone is effective against insulin resistance].
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Thiazoles; Thiazolidinediones | 1999 |
Differential effects of troglitazone and D-chiroinositol on glucosamine-induced insulin resistance in vivo in rats.
Topics: Animals; Chromans; Glucosamine; Glucose Clamp Technique; Hypoglycemic Agents; Inositol; Insulin Resistance; Male; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones; Time Factors; Troglitazone | 1999 |
Amelioration by KRP-297, a new thiazolidinedione, of impaired glucose uptake in skeletal muscle from obese insulin-resistant animals.
Topics: Animals; Blood Glucose; Glucose; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Obesity; Thiazoles; Thiazolidines | 1999 |
Rosiglitazone for type 2 diabetes mellitus.
Topics: Administration, Oral; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 1999 |
A short synthesis of troglitazone: an antidiabetic drug for treating insulin resistance.
Topics: Chromans; Hypoglycemic Agents; Insulin Resistance; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Assessment of human muscle glycogen synthesis and total glucose content by in vivo 13C MRS.
Topics: Adult; Carbon Isotopes; Chromans; Glucose; Glucose Clamp Technique; Glycogen; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Magnetic Resonance Spectroscopy; Male; Middle Aged; Muscle, Skeletal; Obesity; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis.
Topics: 3T3 Cells; Adipocytes; Amino Acid Substitution; Animals; Base Sequence; Cell Differentiation; Codon; COS Cells; DNA Primers; Genes, Reporter; Insulin Resistance; Luciferases; Mice; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation | 2000 |
Novel oximes having 5-benzyl-2,4-thiazolidinedione as antihyperglycemic agents: synthesis and structure-activity relationship.
Topics: Animals; Blood Glucose; Drug Evaluation; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Isomerism; Mice; Mice, Inbred Strains; Oximes; Receptors, Cytoplasmic and Nuclear; Structure-Activity Relationship; Thiazoles; Transcription Factors | 2000 |
Troglitazone improves recovery of left ventricular function after regional ischemia in pigs.
Topics: Animals; Blood Pressure; Chromans; Hypoglycemic Agents; Insulin Resistance; Myocardial Ischemia; Oxygen Consumption; Swine; Thiazoles; Thiazolidinediones; Troglitazone; Ventricular Function, Left | 2000 |
["Insulin sensitizers" (glitazones), obesity, insulin resistance--is there a connection?].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Obesity; Peroxisome Proliferators; Thiazoles | 2000 |
Thiazolidinediones: an update.
Topics: Adipose Tissue; Diabetes Mellitus; DNA-Binding Proteins; Humans; Insulin Resistance; Molecular Conformation; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors | 2000 |
Troglitazone prevents and reverses dexamethasone induced insulin resistance on glycogen synthesis in 3T3 adipocytes.
Topics: 3T3 Cells; Abortifacient Agents, Steroidal; Adipocytes; Animals; Binding Sites; Chromans; Dexamethasone; Dose-Response Relationship, Drug; Drug Interactions; Glucocorticoids; Glycogen; Hypoglycemic Agents; Insulin; Insulin Resistance; Iodine Radioisotopes; Mice; Mifepristone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Thiazolidinediones exert different effects on insulin resistance between dexamethasone-treated rats and wistar fatty rats.
Topics: Animals; Chromans; Dexamethasone; Drug Combinations; Glucocorticoids; Glucose; Glucose Clamp Technique; Homeostasis; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Obesity; Pioglitazone; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Insulin sensitizers and antiandrogens in the treatment of polycystic ovary syndrome.
Topics: Androgen Antagonists; Chromans; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Syndrome; Pregnancy; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[New antidiabetic in "virtual reality". Eye to eye with insulin resistance].
Topics: Computer Simulation; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; User-Computer Interface | 2000 |
v- and t-SNARE protein expression in models of insulin resistance: normalization of glycemia by rosiglitazone treatment corrects overexpression of cellubrevin, vesicle-associated membrane protein-2, and syntaxin 4 in skeletal muscle of Zucker diabetic fat
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gene Expression; Glucose Transporter Type 4; Hypoglycemic Agents; Immunoblotting; Insulin Resistance; Male; Membrane Proteins; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Obesity; Qa-SNARE Proteins; R-SNARE Proteins; Rats; Rats, Sprague-Dawley; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Vesicle-Associated Membrane Protein 3 | 2000 |
Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Topics: Adult; Arteriosclerosis; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Female; Fibrinolysis; Glucose Clamp Technique; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Obesity; Plasminogen Activator Inhibitor 1; Thiazoles; Thiazolidinediones; Tissue Plasminogen Activator; Troglitazone | 2000 |
[Tackling insulin resistance. Control of etiology in type 2 diabetes].
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Insulin resistance: a problem for clinicians and scientists.
Topics: Aged; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors | 2000 |
[Troglitazone, an insulin action enhancer--a drug of precision to treat adult-onset diabetes].
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
[New insulin sensitizers].
Topics: Adult; Aged; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Middle Aged; Thiazoles | 1999 |
Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Contraindications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[A 75-year-old type 2 diabetes mellitus case responding strikingly troglitazone: possible mechanism of insulin resistance induced by insulin antibody].
Topics: Aged; Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Antibodies; Insulin Resistance; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Lipoatrophy, lipodystrophy, and insulin resistance.
Topics: Body Composition; Chromans; Diabetes Mellitus, Lipoatrophic; Humans; Hypoglycemic Agents; Insulin Resistance; Lipodystrophy; Syndrome; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Retinoid X receptor agonists have anti-obesity effects and improve insulin sensitivity in Zucker fa/fa rats.
Topics: Analysis of Variance; Animals; Blood Glucose; Body Weight; Eating; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Nicotinic Acids; Obesity; Rats; Rats, Zucker; Receptors, Retinoic Acid; Retinoid X Receptors; Rosiglitazone; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors | 2000 |
Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice.
Topics: Animals; Arteriosclerosis; Base Sequence; CD36 Antigens; DNA Primers; Female; Gene Expression; Humans; Insulin Resistance; Ligands; Male; Matrix Metalloproteinase 9; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxazoles; Receptors, Cytoplasmic and Nuclear; Receptors, Immunologic; Receptors, LDL; Receptors, Lipoprotein; Receptors, Scavenger; RNA, Messenger; Rosiglitazone; Scavenger Receptors, Class B; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha; Tyrosine | 2000 |
Rosiglitazone.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Food-Drug Interactions; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Thiazoles; Thiazolidinediones; United States | 2000 |
[Diabetes therapy related to etiology. Indications, uses and side effects of new insulin sensitizers].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
[First insulin sensitizer approved in Germany. Insulin resistance in type 2 diabetes can be treated].
Topics: Diabetes Mellitus, Type 2; Drug Approval; Germany; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Beneficial insulin-sensitizing and vascular effects of S15261 in the insulin-resistant JCR:LA-cp rat.
Topics: Animals; Blood Glucose; Body Weight; Chromans; Eating; Fluorenes; Gene Expression; Glucose Tolerance Test; Glucose-6-Phosphatase; Hypoglycemic Agents; In Vitro Techniques; Insulin; Insulin Resistance; Lactic Acid; Lipids; Liver; Male; Mesenteric Arteries; Metformin; Muscle Relaxation; Muscle, Smooth, Vascular; Phosphoenolpyruvate Carboxylase; Rats; RNA, Messenger; Thiazoles; Thiazolidinediones; Troglitazone; Vascular Resistance | 2000 |
[Insulin sensitizer. A new therapy option for type 2 diabetic patients].
Topics: Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Effects of a low-energy diet and an insulin-sensitizing agent on ambulatory blood pressure in overweight hypertensive patients.
Topics: Adult; Aged; Blood Pressure; Chromans; Diet, Reducing; Female; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Obesity; Thiazoles; Thiazolidinediones; Troglitazone; Weight Loss | 2000 |
Glucose modifies the cross-talk between insulin and the beta-adrenergic signalling system in vascular smooth muscle cells.
Topics: Animals; Cells, Cultured; Chromans; Glucose; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Isoproterenol; Mitogen-Activated Protein Kinases; Muscle, Smooth, Vascular; Phosphatidylinositol 3-Kinases; Phosphoproteins; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, beta; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Renal protective effect of troglitazone in Wistar fatty rats.
Topics: Animals; Blood Pressure; Body Weight; Chromans; Female; Hypoglycemic Agents; Insulin Resistance; Kidney; Proteinuria; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
UCP3 gene expression does not correlate with muscle oxidation rates in troglitazone-treated Zucker fatty rats.
Topics: Animals; Antioxidants; Body Weight; Carbon Dioxide; Carrier Proteins; Chromans; Diabetes Mellitus, Type 2; Disease Models, Animal; Energy Metabolism; Fatty Acids; Gene Expression Regulation; Glucose; Insulin Resistance; Ion Channels; Mitochondrial Proteins; Muscle, Skeletal; Rats; Rats, Zucker; RNA, Messenger; Thiazoles; Thiazolidinediones; Troglitazone; Uncoupling Protein 3 | 2000 |
Dietary fat-induced increase in blood pressure and insulin resistance in rats.
Topics: Adipose Tissue; Animals; Blood Glucose; Blood Pressure; Body Weight; Chromans; Dietary Carbohydrates; Dietary Fats; Dietary Fats, Unsaturated; Fatty Acids, Nonesterified; Hypertension; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Obesity; Rats; Rats, Wistar; Sucrose; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 2000 |
[New prospects for the type 2 diabetic patient. Delaying disease progression].
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Disease Progression; Humans; Hypoglycemic Agents; Insulin Resistance; Prognosis; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
[Causal therapy of type 2 diabetes. Determining the cause of insulin resistance early].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscle cells.
Topics: Adipocytes; Base Sequence; Biomarkers; Cell Differentiation; Cells, Cultured; Chromans; Diabetes Mellitus, Type 2; DNA Primers; Gene Expression; Glucose; Glucose Transporter Type 1; Glucose Transporter Type 4; Glycogen; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
American Diabetes Association 60th Scientific Sessions, 2000: thiazolidinediones, obesity, and related topics.
Topics: Animals; Chemical and Drug Induced Liver Injury; Diabetes Mellitus; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Leptin; Lipids; Obesity; Societies, Medical; Thiazoles | 2001 |
The hormone resistin links obesity to diabetes.
Topics: 3T3 Cells; Adipocytes; Amino Acid Sequence; Animals; Base Sequence; Chromosomes, Human, Pair 19; Cloning, Molecular; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet; DNA; Female; Gene Expression Regulation; Glucose Intolerance; Hormones; Hormones, Ectopic; Humans; Hypoglycemic Agents; Insulin Antagonists; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Molecular Sequence Data; Nerve Growth Factor; Neutralization Tests; Obesity; Proteins; Resistin; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones | 2001 |
[30-year-old diabetic patients mostly have type 2 diabetes. "Mature" diabetics are becoming increasingly younger].
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Pioglitazone; Thiazoles; Thiazolidinediones | 2001 |
Lipid lowering explains the insulin sensitivity enhancing effects of a thiazolidinedione, 5-(4-(2-(2-phenyl-4-oxazolyl)ethoxy)benzyl)-2,4 thiazolidinedione.
Topics: Animals; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Clamp Technique; Insulin; Insulin Resistance; Liver; Obesity; Rats; Rats, Zucker; Thiazoles; Thiazolidinediones; Triglycerides | 2000 |
Troglitazone reduces plasma levels of tumour necrosis factor-alpha in obese patients with type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Obesity; Thiazoles; Thiazolidinediones; Troglitazone; Tumor Necrosis Factor-alpha | 2000 |
Dehydroepiandrosterone suppresses elevated hepatic glucose-6-phosphatase mRNA level in C57BL/KsJ-db/db mice: comparison with troglitazone.
Topics: Animals; Blood Glucose; Blotting, Northern; Body Weight; Chromans; Dehydroepiandrosterone; Diabetes Mellitus; Glucose-6-Phosphatase; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Organ Size; RNA, Messenger; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Insulin resistance and nonalcoholic steatohepatitis: fat or fiction?
Topics: Chromans; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Lipolysis; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
The role of PPARgamma as a thrifty gene both in mice and humans.
Topics: Adipose Tissue; Animals; Case-Control Studies; Diabetes Mellitus, Type 2; Dietary Fats; Humans; Hypertrophy; Insulin Resistance; Leptin; Mice; Mice, Knockout; Models, Biological; Obesity; Polymorphism, Genetic; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2000 |
Insulin resistance with enhanced insulin signaling in high-salt diet-fed rats.
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinases; Deoxyglucose; Diet, Sodium-Restricted; Enzyme Activation; Glucose Clamp Technique; Glycogen Synthase; Glycogen Synthase Kinase 3; Glycogen Synthase Kinases; In Vitro Techniques; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Intracellular Signaling Peptides and Proteins; Liver; Male; Muscle, Skeletal; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Receptor, Insulin; Signal Transduction; Thiazoles; Thiazolidinediones; Tyrosine | 2001 |
Effects of troglitazone and temocapril in spontaneously hypertensive rats with chronic renal failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Chromans; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Kidney; Kidney Failure, Chronic; Male; Proteinuria; Rats; Rats, Inbred SHR; Thiazepines; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Troglitazone stimulates pancreatic growth in congenitally CCK-A receptor-deficient OLETF rats.
Topics: Aging; Amylases; Animals; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Fibrosis; Homeostasis; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipase; Male; Pancreas; Rats; Rats, Inbred OLETF; Receptor, Cholecystokinin A; Receptors, Cholecystokinin; Reference Values; Thiazoles; Thiazolidinediones; Troglitazone; Trypsin | 2001 |
A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport.
Topics: Animals; Apolipoprotein A-I; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Biological Transport; Blood Glucose; Cell Line; Cholesterol; Cholesterol, HDL; Drug Design; Fasting; Fibroblasts; Humans; Hyperinsulinism; Insulin; Insulin Resistance; Intestinal Mucosa; Intestines; Macaca mulatta; Macrophages; Male; Metabolic Diseases; Obesity; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Substrate Specificity; Thiazoles; Transcription Factors; Triglycerides | 2001 |
Administration of troglitazone, but not pioglitazone, reduces insulin resistance caused by short-term dexamethasone (DXM) treatment by accelerating the metabolism of DXM.
Topics: Administration, Oral; Blood Glucose; Chromans; Dexamethasone; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metabolic Clearance Rate; Pioglitazone; Reference Values; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats.
Topics: Animals; Antihypertensive Agents; Base Sequence; Chromans; Disease Models, Animal; DNA Primers; Glomerulosclerosis, Focal Segmental; Hypoglycemic Agents; Insulin Resistance; Kidney; Lipids; Macrophages; Male; Nephrectomy; Plasminogen Activator Inhibitor 1; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factors; Transforming Growth Factor beta; Troglitazone | 2001 |
Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator--activated receptor-gamma.
Topics: 3T3 Cells; Adipocytes; Animals; Cell Differentiation; Cell Line; Deoxyglucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Mice; Phosphatidylinositol 3-Kinases; Phosphorylation; Phosphotyrosine; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Thiazoles; Thiazolidinediones; Transcription Factors; Transfection; Transforming Growth Factor alpha | 2001 |
The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance.
Topics: 3T3 Cells; Adipocytes; Animals; CCAAT-Enhancer-Binding Proteins; Cell Differentiation; Cell Division; Cell Nucleus; DNA-Binding Proteins; HIV Protease Inhibitors; Indinavir; Insulin; Insulin Resistance; Mice; Rosiglitazone; Stem Cells; Sterol Regulatory Element Binding Protein 1; Thiazoles; Thiazolidinediones; Time Factors; Tissue Distribution; Transcription Factors | 2001 |
Comparison of the metabolic effects of metformin and troglitazone on fructose-induced insulin resistance in male Sprague-Dawley rats.
Topics: Animals; Chromans; Fatty Acids, Nonesterified; Fructose; Hypoglycemic Agents; Insulin Resistance; Leptin; Male; Metformin; Rats; Rats, Sprague-Dawley; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Insulin-sensitizing action of rosiglitazone is enhanced by preventing hyperphagia.
Topics: Animals; Body Weight; Carrier Proteins; Eating; Food Deprivation; Hyperphagia; Hypoglycemic Agents; Hypothalamus; Insulin Resistance; Ion Channels; Leptin; Male; Mitochondrial Proteins; Neuropeptide Y; Obesity; Rats; Rats, Wistar; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Uncoupling Protein 3 | 2001 |
Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle.
Topics: Analysis of Variance; Animals; Barium; Calcium; Chromans; Dose-Response Relationship, Drug; Electric Stimulation; Female; Guinea Pigs; Humans; Insulin Resistance; Ion Channels; Isoxazoles; Membrane Potentials; Muscle, Smooth, Vascular; Pioglitazone; Potassium Channels; Prostaglandin D2; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Troglitazone improves whole-body insulin resistance and skeletal muscle glucose use in type II diabetic patients.
Topics: Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Fluorodeoxyglucose F18; Glucose; Humans; Hypertension; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Muscle, Skeletal; Radiopharmaceuticals; Thiazoles; Thiazolidinediones; Tomography, Emission-Computed; Troglitazone | 2001 |
Effects of troglitazone and voluntary running on insulin resistance induced high fat diet in the rat.
Topics: Animals; Blood Glucose; Body Weight; Chromans; Dietary Fats; Female; Glucose; Glucose Clamp Technique; Glycogen; Hypoglycemic Agents; Insulin; Insulin Resistance; Muscle, Skeletal; Rats; Rats, Wistar; Running; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
A thiazolidinedione improves in vivo insulin action on skeletal muscle glycogen synthase in insulin-resistant monkeys.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Glucose Clamp Technique; Glucose-6-Phosphate; Glycogen Synthase; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Insulin Resistance; Macaca mulatta; Male; Muscle, Skeletal; Obesity; Thiazoles | 2000 |
Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance.
Topics: Adipocytes; Adipose Tissue; Analysis of Variance; Animals; Blood Glucose; Cell Division; Cell Size; DNA; Fatty Acids, Nonesterified; Feeding Behavior; Female; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Resistance; Magnetic Resonance Imaging; Obesity; Pioglitazone; Rats; Rats, Zucker; Thiazoles; Thiazolidinediones; Thinness; Triglycerides; Weight Gain | 2001 |
Troglitazone improves endothelial dysfunction in patients with insulin resistance.
Topics: Adult; Arteriosclerosis; Brachial Artery; Case-Control Studies; Chromans; Endothelium, Vascular; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Thiazoles; Thiazolidinediones; Troglitazone; Vasodilation | 2000 |
A comparison of the effects of troglitazone and vitamin E on the fatty acid composition of serum phospholipids in an experimental model of insulin resistance.
Topics: Animals; Antioxidants; Blood Glucose; Blood Pressure; Chromans; Disease Models, Animal; Fatty Acids; Female; Hyperinsulinism; Hypertriglyceridemia; Hypoglycemic Agents; Insulin Resistance; Rats; Rats, Mutant Strains; Rats, Wistar; Thiazoles; Thiazolidinediones; Troglitazone; Vitamin E | 2001 |
Mechanisms involved in tumor necrosis factor-alpha induction of insulin resistance and its reversal by thiazolidinedione(s).
Topics: Animals; Autoradiography; Carcinoma, Hepatocellular; Chromans; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Insulin Resistance; Ligands; Liver Neoplasms; Rats; Thiazoles; Thiazolidinediones; Troglitazone; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2001 |
Insulin resistance induced in dairy steers by tumor necrosis factor alpha is partially reversed by 2,4-thiazolidinedione.
Topics: Animals; Blood Glucose; Cattle; Fatty Acids, Nonesterified; Glucagon; Glucose; Growth Hormone; Growth Hormone-Releasing Hormone; Insulin; Insulin Resistance; Male; Random Allocation; Recombinant Proteins; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2001 |
[ACE inhibitor plus glitazone. Insulin sensitizer, preventing diabetes?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Insulin Resistance; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance.
Topics: Adipocytes; Animals; Heterozygote; Insulin; Insulin Resistance; Liver; Mice; Muscles; Obesity; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Thiazoles; Transcription Factors; Triglycerides; Up-Regulation | 2001 |
Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-gamma-mediated changes in gene expression.
Topics: Animals; Chromans; Cycloheximide; Dactinomycin; Drug Interactions; Energy Metabolism; Gene Expression; In Vitro Techniques; Insulin Resistance; Ligands; Male; Muscle, Skeletal; Nucleic Acid Synthesis Inhibitors; Protein Synthesis Inhibitors; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Troglitazone | 2001 |
Thiazolidinedione treatment prevents free fatty acid-induced insulin resistance in male wistar rats.
Topics: Animals; CD36 Antigens; Chromans; Emulsions; Fat Emulsions, Intravenous; Fatty Acids, Nonesterified; Glucose; In Vitro Techniques; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Lecithins; Ligands; Liver; Male; Membrane Glycoproteins; Muscle, Skeletal; Organic Anion Transporters; Phosphoinositide-3 Kinase Inhibitors; Phosphoproteins; Phosphorylation; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Safflower Oil; Soybean Oil; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tyrosine | 2001 |
Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes.
Topics: 3T3 Cells; Adipose Tissue; Animals; Benzhydryl Compounds; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Epoxy Compounds; Fatty Acids; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Leptin; Mice; Mice, Knockout; Nicotinic Acids; Obesity; Receptors, Adrenergic, beta-3; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Rosiglitazone; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
[Glitazones--a new therapeutic principle in diabetes].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity.
Topics: Adipocytes; Amino Acids; Animals; Binding Sites; Blood Glucose; Body Weight; Cell Differentiation; Cell Line; Dose-Response Relationship, Drug; Fluorenes; Gene Expression Regulation; Genes, Reporter; Hypoglycemic Agents; Insulin Resistance; Leucine; Ligands; Male; Mice; Mice, Inbred Strains; Molecular Structure; Protein Binding; Protein Conformation; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Rosiglitazone; Spectrometry, Mass, Electrospray Ionization; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Tyrosine | 2001 |
Phosphodiesterase 3B gene expression is enhanced in the liver but reduced in the adipose tissue of obese insulin resistant db/db mouse.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adipose Tissue; Animals; Blood Glucose; Blotting, Western; Chromans; Cyclic Nucleotide Phosphodiesterases, Type 3; Fatty Acids, Nonesterified; Gene Expression Regulation, Enzymologic; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Obese; RNA, Messenger; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 2001 |
Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats.
Topics: 3T3 Cells; Adipocytes; Adipose Tissue; Administration, Oral; Animals; Blood Glucose; Body Weight; Glucose; Glucose Clamp Technique; Glucose Transporter Type 1; Glucose Transporter Type 4; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mice; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Obesity; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Thinness | 2001 |
[A role of the PPAR gamma activation in insulin resistance].
Topics: Adipocytes; Animals; CCAAT-Enhancer-Binding Proteins; Cell Differentiation; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Energy Metabolism; Humans; Insulin Resistance; Mice; Mutation; Receptors, Cytoplasmic and Nuclear; Sterol Regulatory Element Binding Protein 1; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
[Infarct prevention for diabetics. To lower blood sugar is not enough].
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fibrinolytic Agents; Humans; Hypoglycemic Agents; Insulin Resistance; Myocardial Infarction; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Vasodilator Agents | 2001 |
[Oral therapy in type 2 diabetes. Critical evaluation of glitazones].
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
A treatment for Mr WP: thiazolidinediones after troglitazone.
Topics: Aged; Animals; Body Mass Index; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Mice, Knockout; Obesity; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2002 |
C(2)-ceramide influences the expression and insulin-mediated regulation of cyclic nucleotide phosphodiesterase 3B and lipolysis in 3T3-L1 adipocytes.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3T3 Cells; Adipocytes; Animals; Blotting, Western; Chromans; Cyclic AMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 3; Drug Interactions; Enzyme Inhibitors; Insulin; Insulin Resistance; Isoquinolines; Lipolysis; Mice; Receptors, Cytoplasmic and Nuclear; Sphingosine; Sulfonamides; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Necrosis Factor-alpha | 2002 |
Rosiglitazone treatment of patients with extreme insulin resistance and diabetes mellitus due to insulin receptor mutations has no effects on glucose and lipid metabolism.
Topics: Adolescent; Adult; Apolipoproteins B; Body Mass Index; Diabetes Complications; Diabetes Mellitus; Fatty Acids, Nonesterified; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mutation; Plasminogen Activator Inhibitor 1; Receptor, Insulin; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 2001 |
Troglitazone stimulates pancreatic growth in normal rats.
Topics: Aging; Alanine Transaminase; Amylases; Animals; Aspartate Aminotransferases; Blood Glucose; Body Weight; Cholecystokinin; Chromans; Diet; DNA; Eating; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Organ Size; Pancreas; Proteins; Rats; Rats, Long-Evans; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2002 |
A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Dose-Response Relationship, Drug; Energy Intake; Energy Metabolism; Glucose Tolerance Test; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Metabolic Syndrome; Mice; Mice, Mutant Strains; Organic Chemicals; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Heart; Heart Rate; Hypoglycemic Agents; Insulin Resistance; Myocardial Ischemia; Myocardial Reperfusion; Obesity; Organ Size; Perfusion; Rats; Rats, Zucker; Reference Values; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors | 2002 |
The effect of troglitazone on plasma homocysteine, hepatic and red blood cell S-adenosyl methionine, and S-adenosyl homocysteine and enzymes in homocysteine metabolism in Zucker rats.
Topics: Animals; Chromans; Cystathionine beta-Synthase; Erythrocytes; Female; Homocysteine; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Methylenetetrahydrofolate Reductase (NADPH2); Obesity; Oxidoreductases Acting on CH-NH Group Donors; Rats; Rats, Zucker; S-Adenosylhomocysteine; S-Adenosylmethionine; Thiazoles; Thiazolidinediones; Thinness; Troglitazone | 2002 |
Ameliorated hepatic insulin resistance is associated with normalization of microsomal triglyceride transfer protein expression and reduction in very low density lipoprotein assembly and secretion in the fructose-fed hamster.
Topics: Animal Nutritional Physiological Phenomena; Animals; Apolipoproteins B; Cricetinae; Fructose; Hepatocytes; Hypoglycemic Agents; Immunoblotting; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Intracellular Signaling Peptides and Proteins; Lipoproteins, VLDL; Liver; Male; Mesocricetus; Microsomes, Liver; Perfusion; Phosphoproteins; Phosphorylation; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Time Factors; Triglycerides | 2002 |
Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
Topics: Abdomen; Adipose Tissue; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Pioglitazone; Regression Analysis; Thiazoles; Thiazolidinediones | 2002 |
Troglitazone inhibits growth and improves insulin signaling by suppression of angiotensin II action in vascular smooth muscle cells from spontaneously hypertensive rats.
Topics: Angiotensin II; Animals; Arteriosclerosis; Cell Division; Cells, Cultured; Chromans; Depression, Chemical; DNA; Growth Substances; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Muscle, Smooth, Vascular; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Signal Transduction; Thiazoles; Thiazolidinediones; Troglitazone; Tyrosine | 2002 |
Pharmacological treatments for GH-induced insulin resistance.
Topics: Animals; Blood Gas Analysis; Blood Glucose; Chromans; Drug Interactions; Human Growth Hormone; Hypoglycemic Agents; Inositol; Insulin; Insulin Resistance; Male; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Does hypertriglyceridemia present an indication for pioglitazone therapy in diabetes?
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypertriglyceridemia; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
Comparison of the extrapancreatic action of BRX-220 and pioglitazone in the high-fat diet-induced insulin resistance.
Topics: Animals; Dietary Fats; Hydroxylamines; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Muscle, Skeletal; Pancreas; Pioglitazone; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones | 2002 |
Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models.
Topics: Animals; Diabetic Neuropathies; Guanidines; Hydroxylamines; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Pioglitazone; Rats; Rats, Wistar; Rats, Zucker; Streptozocin; Thiazoles; Thiazolidinediones | 2002 |
Pioglitazone increases insulin sensitivity by activating insulin receptor kinase.
Topics: Administration, Oral; Animals; Diabetes Mellitus, Type 2; Drug Hypersensitivity; Electrophoresis, Polyacrylamide Gel; Enzyme Activation; Female; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Obesity; Phosphorylation; Pioglitazone; Protein-Tyrosine Kinases; Rats; Rats, Inbred Strains; Receptor, Insulin; Thiazoles; Thiazolidinediones | 1992 |
Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents.
Topics: Animals; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Mice; Pioglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones | 1992 |
Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression.
Topics: Animals; Crosses, Genetic; Diabetes Mellitus; Diabetes Mellitus, Experimental; Female; Hypoglycemic Agents; Insulin; Insulin Resistance; Kinetics; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Monosaccharide Transport Proteins; Obesity; Phosphoenolpyruvate Carboxykinase (GTP); Pioglitazone; RNA, Messenger; Thiazoles; Thiazolidinediones | 1992 |
The effect of CP 68,722, a thiozolidinedione derivative, on insulin sensitivity in lean and obese Zucker rats.
Topics: Animals; Benzopyrans; Glucose; Glucose Clamp Technique; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Obesity; Osmolar Concentration; Rats; Rats, Zucker; Reference Values; Thiazoles; Thiazolidinediones | 1991 |
Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats.
Topics: Adipose Tissue; Animals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose; Glucose Tolerance Test; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Muscles; Obesity; Pioglitazone; Rats; Rats, Inbred Strains; Thiazoles; Thiazolidinediones | 1990 |
Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats.
Topics: Animals; Blood Glucose; Body Weight; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Pioglitazone; Rats; Rats, Inbred Strains; Thiazoles; Thiazolidinediones; Triglycerides | 1990 |
Insulinlike activity of new antidiabetic agent CP 68722 in 3T3-L1 adipocytes.
Topics: Adipose Tissue; Animals; Benzopyrans; Biological Transport; Cell Line; Cells, Cultured; Deoxyglucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucose; Insulin; Insulin Resistance; Oxidation-Reduction; Receptor, Insulin; Sulfonylurea Compounds; Temperature; Thiazoles; Thiazolidinediones | 1990 |
Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals.
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Experimental; Dogs; Glucose; Glucose Tolerance Test; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Male; Mice; Mice, Inbred Strains; Mice, Obese; Pioglitazone; Rats; Rats, Inbred Strains; Rats, Zucker; Species Specificity; Thiazoles; Thiazolidinediones | 1990 |
Insulin resistance is accompanied by impairment of amylase-gene expression in the exocrine pancreas of the obese Zucker rat.
Topics: Amylases; Animals; Female; Gene Expression Regulation; Glucose; Insulin Resistance; Obesity; Pancreas; Protein Biosynthesis; Rats; Rats, Mutant Strains; Rats, Zucker; RNA, Messenger; Thiazoles; Thiazolidinediones | 1986 |
A potent in vivo effect of ciglitazone on muscle insulin resistance induced by high fat feeding of rats.
Topics: Animals; Blood Glucose; Deoxyglucose; Dietary Fats; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Muscles; Phosphorylation; Rats; Rats, Inbred Strains; Thiazoles; Thiazolidinediones | 1989 |
Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats.
Topics: Adipose Tissue; Animals; Benzopyrans; Blood Glucose; Chromans; Deoxyglucose; Diabetes Mellitus, Experimental; Fatty Acids, Nonesterified; Hypoglycemic Agents; Insulin; Insulin Resistance; Ketone Bodies; Lactates; Lactic Acid; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Rats; Rats, Inbred Strains; Rats, Zucker; Receptor, Insulin; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 1988 |
Insulin receptor and postbinding defects in KK mouse adipocytes and improvement by ciglitazone.
Topics: 3-O-Methylglucose; Adipose Tissue; Animals; Carbon Radioisotopes; Cells, Cultured; Diabetes Mellitus, Experimental; Glucose; Glycolysis; Hypoglycemic Agents; Insulin Resistance; Kinetics; Male; Methylglucosides; Methylglycosides; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Receptor, Insulin; Thiazoles; Thiazolidinediones; Tritium | 1988 |
Effects of ciglitazone on insulin resistance and thermogenic responsiveness to acute cold in brown adipose tissue of genetically obese (ob/ob) mice.
Topics: Adipose Tissue, Brown; Animals; Cold Temperature; Guanosine Diphosphate; Insulin; Insulin Resistance; Lipids; Male; Mice; Mice, Obese; Mitochondria; Thiazoles; Thiazolidinediones | 1986 |